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ABSTRACT 
Chromosomal instability (CIN), characterised by alterations in structure and 
number of chromosomes, is a feature common to oral cancer. The 
mechanism(s) underlying this phenomenon, however, is unknown. This study 
examined the mitotic and tetraploidy checkpoints and centrosomes in a panel of 
seven human oral squamous cell carcinoma (OSCC)-derived cell lines. The 
results showed that the mitotic checkpoint was attenuated in five cell lines and 
indicated that the tetraploidy checkpoint was defective in two cell lines. 
Numerical and morphological centrosome abnormalities were observed in five 
of the seven cell lines. The centrosomes were able to nucleate microtubules in 
all cells but defects in the ability of cells to monitor the numbers of microtubules 
nucleated were observed in two cell lines. Analysis of clonal cell populations 
further showed that cells containing centrosome abnormalities might have an 
intrinsic inability to maintain normal centrosome numbers. 
Centrosome abnormalities were also examined in archival paraffin-embedded 
oral tissues. Centrosome abnormalities were detected in 100% of dysplasias 
(28/28) and OSCCs (17/17). The percentage of cells with abnormal 
centrosomes increased during the transition from dysplasia to SCC and 
correlated with a loss of tumour cell differentiation. The results suggest that 
these abnormalities appear early in the development of oral cancer and 
contribute to tumour aggressiveness. Centrosome abnormalities in dysplasias 
occurred irrespective of ploidy status, indicating that these abnormalities 
precede CIN during disease progression. 
In an attempt to develop an in vitro model of CIN, human immortalised normal 
oral keratinocytes were treated with the carcinogen 2-amino-l-methyl-6- 
phenylimidazo[4,5-b]pyridine (PhIP). Development of PhIP resistance resulted 
in consistent chromosomal gains and not a dynamic CIN. The response of the 
PhIP-resistant clones to irradiation induced DNA damage, in terms of cell 
viability, induction of apoptosis, activation of the p53 pathway and cell cycle 
arrest was similar to parental control cells indicating that the induction of PhIP- 
resistance was not associated with resistance to other forms of DNA damage. 
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1.1 GENERAL INTRODUCTION 
There is increasing evidence that the majority of cancers are genetically 
unstable and exhibit an abnormal chromosome content, a phenomenon referred 
to as aneuploidy (Rajagopalan et al., 2004). Based on the numerous studies, 
which have demonstrated large-scale genomic alterations in solid tumours, a 
theory known as the aneuploidy hypothesis is being recognised as a plausible 
explanation for the complex karyotypes observed in cancer. The underlying 
mechanism(s) responsible for this phenomenon, however, remains to be 
determined. It has been postulated that defects in the machineries monitoring 
chromosome segregation and structure could lead to aneuploidy and recent 
studies indicate that abnormalities of the mitotic and tetraploidy checkpoints and 
centrosomes may be the underlying cause of genomic instability in a variety of 
cancers. 
Recently, the aneuploid status of premalignant lesions of the oral cavity has 
been shown to predict malignant progression and patient survival (Sudbo et al., 
2001 a; 2001b; 2004), indicating that aneuploidy could be used as a diagnostic 
and prognostic marker. Even though a correlation between aneuploidy and 
malignant progression has been established in oral cancer, very little is known 
of the underlying mechanisms responsible for this genetic instability and this 
forms the basis of the present study. 
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1.2 CURRENT THEORIES FOR THE EVOLUTION OF CANCER 
A common characteristic of solid tumours is a complex karyotype. A genomic 
destabilisation-initiated carcinogenesis model has been postulated to explain 
the complex and highly varied karyotypes and phenotypes of these tumours. 
Two main theories, namely the gene mutation (Zimonjic et al., 2001) and 
aneuploidy (Li et al., 2000) hypothesis, have been proposed to explain the 
genomic destabilisation observed in cancers. 
The proponents of the mutation hypothesis suggest that the accumulation of 
somatic mutations is responsible for carcinogenesis. The hypothesis predicts 
that carcinogens function as mutagens, creating cancer specific mutations with 
oncogenic properties. The hypothesis is questioned, however, due to the 
emergence of nongenotoxic carcinogens, the absence of cancer-specific gene 
mutations and the long latency period between carcinogen treatment and 
emergence of cancer (Duesberg and Rasnick, 2000). Because the normal rate 
of mutation could not account for the multiple mutations observed in cancer, 
Loeb and co-workers (Loeb, 2001; Loeb at al., 2003) put forward the mutator 
phenotype theory in support of the mutation theory. They proposed that 
mutations in genes responsible for the maintenance of genomic stability results 
in an increased mutation rate and this, in turn, drives tumour progression. Other 
mathematical models of tumorigenesis have favoured the selection of 
advantageous mutations over increased mutation rates (Tomlinson et al., 1996), 
suggesting that most tumours start with a normal intrinsic mutation rate but the 
subsequent clonal expansion of advantageous mutations drives tumorigenesis. 
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Recently, the aneuploidy hypothesis was revived as an alternative explanation 
for the complex karyotypes observed in most solid tumours (Li et at., 2000). In 
this theory, genomic destabilisation occurs as a result of alterations in the 
proteins that segregate, synthesize and repair chromosomes, resulting in an 
altered chromosome number or structure and an increased spontaneous rate of 
gene mutations following every cell division, producing new genomically 
unstable preneoplastic and neoplastic progeny cells that do not resemble their 
precursor cells. These progeny cells are constantly evolving due to their 
unstable genome to create progenies with new karyotypes (Duesberg and 
Rasnick, 2000; Duesberg and Li, 2003; Duesberg et al., 2004). Consistently, 
both karyotypic (Duesberg at al., 1998) and chromosome structure (Fabarious 
at al., 2003) instability has been shown to be proportional to the degree of 
aneuploidy; the more aneuploid the cell, the more unstable the genotype. 
In view of the ongoing debate, the field of genomic instability is highly 
controversial. In spite of reports of independent mechanisms leading to genetic 
instability, it is possible that the mutation and aneuploidy hypotheses are not 
mutually exclusive and could potentially synergise to promote the destabilization 
of the genome. 
1.3 GENOMIC INSTABILITY 
To date, genomic instability has been shown to exist at two distinct levels. In a 
small subset of tumours, the instability is observed at the nucleotide level and 
results in base substitution, deletion or insertion of a few nucleotides, whilst in 
most other cancers, the instability is observed at the chromosomal level, 
resulting in loss of heterozygosity (LOH), structural abnormalities and losses 
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and gains of whole chromosomes (Lengaur of al., 1998). Studies on colorectal 
tumours have confirmed that genetic instability occurs in two mutually exclusive 
forms namely, microsatellite instability (MIN) or chromosomal instability (CIN; 
Lengaur et al., 1997). 
1.3.1 Microsatellite instability (MIN) 
The MIN phenotype was described in cancer following the discovery of a subset 
of hereditary non-polyposis colorectal cancers (HNPCC) exhibiting germline 
mutations of mismatch repair (MMR) genes, namely hMSH2, hMSH6, hMLHI, 
hPMS1 and hPMS2 (Buermeyer et al., 1999). 
The MMR pathway functions to remove nucleotides mispaired by DNA 
polymerases and insertion/deletion loops (1-10bp) that results from slippage 
during replication of repetitive sequences or recombination (Hoeijmakers, 
2001). Inactivating alterations of the MMR genes leads to an inability to 
recognize and repair errors that occur during DNA replication. Mutations in the 
hMLH1 and hMSH2 genes account for the majority of mismatch repair defects 
(Buermeyer et a/., 1999; Jiricny and Lahti, 2000). Simple repeat sequences or 
microsatellites at both the non-coding and coding regions of genes are specific 
targets for mutations in MIN cells (Yamasaki and Mironov, 2000) giving rise to 
mutations at the nucleotide level (Jiricny, 1998) resulting in an elevated 
nucleotide mutation rate. The majority of MIN cancers are diploid or near diploid 
and exhibit normal rates of gross chromosomal change. 
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1.3.2 Chromosomal instability (CIN) 
CIN is defined as an accelerated rate of gains or losses of whole or large 
portions of chromosomes (Rajagopalan at al., 2004). CIN manifests itself at the 
chromosomal level and is characterized at the cytogenetic level by marked 
aneuploidy, caused by DNA amplifications, chromosomal loss or gain, and 
allelic losses of chromosome arms (Lengauer et al., 1998). However, the 
existence of aneuploidy in the static state of the cell, does not indicate the 
presence of CIN, as CIN is a measure of flux in the karyotype leading to a 
nondiploid genome (Lengaur at al., 1997). CIN tumours are usually MMR 
proficient. 
The presence of aneuploidy early in human neoplasia suggests that CIN could 
be the cause and not the consequence of the carcinogenic process (Shih at al., 
2001). Further, support from mathematical models of cancer initiation indicates 
that the first event in many sporadic cancers is a heritable alteration that affects 
genetic instability (Nowak at al., 2002), suggesting that CIN is an early event 
and the driving force of cancer progression (Komarova et a/., 2003). 
1.4 HYPOTHETICAL MODEL OF INITIATION AND PROGRESSION OF 
CIN 
A two-stage mechanism has been proposed to explain the complex karyotype 
of the aneuploid cell (Figure 1.1; Duesberg and Rasnick, 2000; Li eta!., 2000). 
In stage one, a carcinogen functions to induce aneuploidy and initiates 
carcinogenesis by generating a preneoplastic aneuploid cell. The compound 
achieves this by altering, either physically or chemically, the chromosomes or 
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the mitotic apparatus. These preneoplastic karyotypes would include aneuploid 
cells that are immortal but not necessarily tumorigenic. This is followed by stage 
two where the aneuploidy itself destabilizes the karyoptype and so catalyses 
karyotypic variation and evolution. The source of the karyotypic instability is the 
imbalance that aneuploidy imparts on the mitotic apparatus resulting in 
missegregation of chromosomes. Thus, the initiated cell evolves 
autocatalytically, generating new lethal, preneoplastic and neoplastic 
karyotypes; the degree of karyotypic instability would be proportional to the 
degree of aneuploidy. The heterogenous karyotype and phenotypic variation 
within a "clonal" cancer, therefore, would be an inevitable consequence of the 
intrinsic instability of an aneuploid karyotype. 
1.5 MECHANISMS UNDERLYING CIN 
Two mechanisms frequently reported to lead to numerical chromosomal 
abnormalities in cancer cells are defects in the mitotic and post-mitotic 
checkpoints (Hartwell, 1992; Andreassen et al., 2001 a) and abnormalities of the 
centrosomes (Ghadimi et al., 2000). In addition, telomeric attrition, the 
progressive shortening of telomeres with each cell division, has been suggested 
to result in some of the structural aberrations of the chromosomes observed in 
malignant tumours (Gisseisson et al., 2001 a). 
1.5.1 Mitotic and post-mitotic checkpoints 
Gross aneuploidy mediated by defects in cell cycle checkpoints have been 
suggested to arise through a two-step process. The first step involves an 
aberrant mitotic exit of cells into G1 with a tetraploid DNA content and, the 
second is an absence of a G1 surveillance mechanism that would prevent cell 
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cycle progression of these cells (Margolis of al., 2003). The first could arise from 
failure of any of the pre-mitotic or mitotic checkpoints and the second, from the 
suppression of the tetraploidy checkpoint. 
1.5.1.1 Mitotic checkpoint 
The mitotic checkpoint, also referred to as the spindle checkpoint, monitors the 
integrity of the random process of kinetochore capture of metaphase 
chromosomes by spindle microtubules during mitosis, ensuring even 
segregation of genetic materials to daughter cells. 
The molecular components of the mitotic checkpoint are encoded by seven 
evolutionarily conserved genes (BUB1-3, MADI-3 and MPSI), first identified in 
budding yeast (Hyot at al., 1991; Li and Murray, 1991; Robert at al., 1994; 
Hardwich and Murray, 1995; Weiss and Winey, 1996). Homologues of some of 
these genes have been demonstrated to be essential for establishing the 
checkpoint response in eukaryotes (Li and Benezra, 1996; Taylor and McKeon, 
1997; Abrieu at al., 2001). Preferential binding to unattached kinetochores 
suggests that these proteins participate in monitoring kinetochore-microtubule 
interactions (Chen at a/., 1996; Chan at al., 1999; Skoufias at al., 2001). 
Unoccupied kinetochores and lack of tension on mono-orientated chromosomes 
have been identified as the source of the mitosis inhibitory signal (Reider at al., 
1994; 1995). 
The downstream target proteins of the checkpoint are the anaphase promoting 
complex/cyclosome (APC/C), a multisubunit E3 ubiquitin ligase that regulates 
the degradation of specific proteins in order to drive mitosis and Cdc2O, a 
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protein that recruits substrates to APC (Peters, 2002; Yu, 2002). In the event of 
inappropriate chromosome capture, Cdc20 is inhibited by the mitotic checkpoint 
complex composed of Mad2, BubR1, Bub3 and Cdc2O, preventing 
ubiquitination of securin by APC. This blocks the enzyme separase from 
causing proteolysis of cohesin, a multiprotein complex that holds the sister- 
chromatids together and, therefore, the metaphase to anaphase transition is 
inhibited (Bharadwaj and Yu, 2004). 
1.5.1.2 Tetraploidy checkpoint 
The tetraploidy checkpoint is a p53-dependent post-mitotic checkpoint (Lanni 
and Jacks, 1998) that functions to elicit a G1 arrest in cells that exit mitosis with 
a tetraploid DNA content (Andreassen et al., 2001a). Tetraploidy could result 
from insults to the DNA or cellular architecture (Andreassen et al., 1996) but the 
checkpoint operates regardless of the mechanism by which the cell becomes 
tetraploid (Andreassen et al., 2001a). Although uncertain, inheritance of double 
the centrosome number following aberrant mitotic exit or ploidy-specific 
regulations of gene expression have been suggested to function as the arrest 
signal (Andreassen et al., 2001 a; 2003). In addition to p53, the checkpoint 
needs intact pRB to function (Borel et al., 2002). p21, a transcriptional target of 
p53, is the main mediator of G1 arrest in tetraploid cells (Andreassen et al., 
2001 b) and acts through the inhibition of cyclin E/Cdk2 activity and binding to 
proliferating-cell nuclear antigen (Stewart at al., 1999). 
1.5.1.3 Cell cycle checkpoints and cancer 
The mitotic checkpoint has been reported to be defective in a number of human 
tumours, including hepatocellular, (Saeki at al., 2002), thyroid (Ouyang at a!., 
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2002) and ovarian cancers (Wang et al., 2002). There is some controversy, 
however, regarding the frequency with which mitotic checkpoint defects occur in 
cancer because studies using the same colorectal cell lines have produced 
conflicting results (Cahill et al., 1998; Tighe et al., 2001). Similarly, Yoon et al. 
(2002) reported mitotic spindle checkpoint defects in breast cancer cell lines, 
data that were contradicted by Blajeski et al. (2002) who demonstrated that the 
same cell lines were able to arrest at lower concentrations of nocodazole. Such 
discrepancies could be due to differences in experimental design, data 
interpretation and the characteristics of the drug used. 
The infrequent occurrence of mutations in checkpoint genes has further 
questioned the role of mitotic checkpoint defects in cancer. Somatic mutations 
in either BUBI or BUBRI were found in only a small fraction of colorectal 
cancers (Cahill et al., 1998). Mutational analysis of the BUB and MAD gene 
family in lung cancer cell lines (Yamaguchi et a/., 1999; Sato et a/., 2000; Haruki 
at al., 2001), breast carcinomas and cell lines (Percy at al., 2000; Langerod et 
a/., 2003), glioblastomas (Reis et al., 2001), colon cancer cell lines (Cahill at a/., 
1999) and bladder cancer (Hernando et al., 2001) also suggests that these 
genes are rarely a target for genetic alteration. A more recent study, however, 
has indicated that nonmutational silencing, such as epigenetic modification of 
mitotic checkpoint genes, may be more important than mutational inactivation 
(Shichiri at al., 2002). An intrinsic elevated rate of chromosome misegregation 
in BUB3+1" mice (Babu et al., 2003) and MAD2+' human cancer cells (Michel at 
al., 2001) suggests that haplo-insufficiency of mitotic checkpoint genes could 
lead to subtle rates of CIN compatible with cell viability. This is consistent with 
the heterozygous alteration (Tsukasaki at a/., 2001; Hempen at a/., 2003) and 
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reduced activity (Ouyang et al., 2002) of mitotic checkpoint genes observed in 
some cancers. Further, sequestration and mislocalization of checkpoint proteins 
by viral oncoproteins is another mechanism of checkpoint inactivation (Kasai at 
al., 2002). 
By contrast to the study of the mitotic checkpoint, our understanding of the 
tetraploidy checkpoint is in its infancy. Tetraploid intermediates appear to be an 
important mechanism of aneuploidization in carcinogenesis (Shackney et al., 
1989) and could act as a direct precursor of aneuploid cells due to their inherent 
instability (Andreassen et al., 1996). Further, the inheritance of increased 
numbers of centrosomes could lead to multipolar mitosis, perpetuating the 
instability caused by the failure of the tetraploid checkpoint (Borel et al., 2002). 
However, a recent study by Uetake and Sluder (2004) has questioned the 
existence of the tetraploidy checkpoint in mammalian cells and suggests that 
the G1 arrest in the tetraploid cells following mitotic exit, described by 
Andreassen et al. (2001a), could be attributed to the subtle disorganization of 
the actin cytoskeleton by the high concentration of dihydrocytochalasin B 
(DCB), a cytokinesis inhibitor, which persisted following drug removal. 
1.5.2 Centrosomes 
The centrosome is the major microtubule-organizing centre (MTOC) of animal 
cells and is crucial for chromosome segregation (Brinkley, 2001) and 
cytokinesis (Piel et al., 2001). Through its control of number, polarity and 
distribution of microtubules, the centrosome coordinates all microtubule-related 
functions such as cell shape, polarity, adhesion, motility, intracellular transport 
and organelle positioning (Fry et al., 2000). The centrosome is needed for 
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progression into S-phase (Hinchcliffe et al., 2001) and has been suggested to 
function as a scaffold for key cell cycle regulators (Fry et al., 2000). Although 
mitotic spindles can form in the absence of centrosomes, the MTOC exerts a 
dominant effect on microtubule organization (Khodjakov et al., 2000). 
1.5.2.1 Centrosome physiology 
Mammalian centrosomes are small non-membranous organelles, often 
associated with the nuclear membrane. They consist of a pair of perpendicularly 
positioned barrel shaped centrioles, surrounded by a mass of amorphous, 
electron dense matrix, termed the pericentriolar material (PCM), which contains 
the y-tubulin ring complexes that nucleate microtubules during interphase and 
mitosis. Each centriole is cylindrical in shape and is built of nine sets of triplet 
microtubules (Fukasawa, 2002). 
1.5.2.2 Centrosome duplication and regulation 
Centrosome duplication is a semi-conservative process, whereby the mother 
centriole acts as a template for daughter centriole formation, and is unique in its 
ability to duplicate itself once every cell cycle (Fry et al., 2000). The centrosome 
duplication cycle in the vertebrate cells consists of several distinct steps (Figure 
1.2). Centriole splitting is followed by the formation of a small structure termed 
the procentriole or daughter centriole at the proximal end, perpendicularly 
oriented to each parental centriole by early S phase; the parental centriole has 
been suggested to act as a template for procentriole formation. Elongation of 
procentrioles occurs throughout S phase and early G2 and centriole maturation 
is completed by the G2 to M phase transition. Finally, the disjunction of the two 
sister centrosomes occurs, each containing a pair of mother-daughter 
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centrioles, signalling the completion of duplication. The physical separation of 
the sister centrosomes to opposite poles of the cell, mediated by microtubule- 
based motor proteins, occurs during the mitotic phase (Balczon, 2000; Stearns 
et al., 2001). 
Centrosome duplication is strictly coordinated with DNA replication, mitosis and 
cell division (Sluder and Hinchcliffe, 2000). Coordination of DNA replication and 
centrosome duplication is dependent upon the phosphorylation status of the 
retinoblastoma protein (Rb), which governs the availability of the E2F 
transcription factor to promote S phase progression, (Meraldi et al., 1999). In 
mammals, the centrosome duplication event is also dependent upon Cyclin 
dependent kinase-2 (Cdk) activation (Lacey et al., 1999), with cyclin E as the 
activating subunit in embryonic cells (Hinchcliffe et al., 1999) and cyclin A in 
somatic cells (Lacey et al., 1999). 
1.5.2.3 Mechanisms of centrosome deregulation 
Centrosome deregulation has been suggested to lead to CIN through its ability 
to mediate abnormal mitosis. There are a number of hypothetical mechanisms 
through which abnormalities in centrosomes could be generated. Excess 
centrosomes can be generated through deregulation of centrosome duplication, 
which could occur either through inappropriate initiation of duplication at late G1 
to early S phase or by uncoupling centrosome duplication from DNA replication 
(Lacey et al., 1999) and by a failure to suppress re-duplication of centrosomes 
through uncontrolled separation of centriole pairs prior to duplication (Sluder 
and Hinchcliffe, 2000). Failure of cytokinesis could also result in cells inheriting 
excess centrosomes (Meraldi at al., 2002) and failure to duplicate or separate 
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centrosomes in mitosis can result in insufficient centrosomes, resulting in 
formation of monopolar spindles and segregation of all the chromosomes into a 
single progeny. Finally, overexpression of PCM components could lead to 
formation of acentriolar centrosomes capable of ectopic microtubule assembly. 
Recent studies strongly suggest that a mechanism centred on mitotic failure 
leading to tetraploidization and the consequential inheritance of extra 
centrosomes, could play an important role in mediating CIN (Figure 1.3; Meraldi 
et al., 2002; Borel et al., 2002). Consistent with this hypothesis, excess 
centrioles that predispose cells to multipolar mitoses and sequential 
appearance of tetraploid and aneuploid cell populations have been observed in 
a mouse model of pancreatic cancer (Levine et al., 1991). This mechanism also 
provides an explanation as to why alterations of multiple genes acting in 
pathways unrelated to centrosome duplication can lead to centrosome 
amplification; co-existence of polyploid cells and centrosome abnormalities, for 
example, have been observed in association with loss of p53 function (Borel et 
al., 2002), mutations in BRCA1 (Xu et al., 1999), BRCA2 (Tuft et al., 1999), 
Skp2 (Nakayama et al., 2000) and overexpression of aurora2 (Meraldi et al., 
2002). 
1.5.2.4 Centrosome abnormalities and cancer 
Centrosome abnormalities are frequently detected in human cancers and 
tumour derived cell lines (Pihan et al., 1998; Ghadimi et al., 2000). The 
abnormalities reported include supernumerary centrosomes, centrosomes of 
different sizes (Sato et a/., 2001), physiological abnormalities including 
disrupted centriole barrel structure, unincorporated microtubule complexes, 
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centrioles of unusual length, and mispositioned centrosomes (Lingle et al., 
1999), increased microtubule nucleating capacity and hyperphosphorylation of 
centrosome-associated proteins (Lingle et a/., 1998). Amongst these, 
abnormalities in centrosome number and size are the most common. 
Deregulation of many cellular proteins have been linked to the centrosomal 
abnormalities observed in cancer, such as loss of p53 activity through mutation 
or deletion (Ouyang et al., 2001), sequestration (Carrol et a/., 1999) and through 
inactivation of downstream targets, p21/Waf1 (Mantel et a/., 1999) and GAAD45 
(Hollander and Fomace, 2002), synergistic overexpression of cyclin E and loss 
of p53 (Kawamura et a/., 2004), overexpression of aurora2/STK15/BTAK (Zhou 
et al., 1998) and mutations in BACR1 (Xu et al., 1999), BACR2 (Tuft et al., 
1999) and Skp2 (Nakayama et al., 2000). 
The presence of centrosomal abnormalities in precancerous lesions (Pihan et 
al., 2003), the high frequency of abnormal mitosis in xenograft models of cancer 
(Shono at al., 2001) and the dynamic karyotypic changes observed in human 
tumours (Lingle et al., 2002) collectively suggests that abnormal centrosomes 
could potentially drive CIN and, in turn, carcinogenesis through chromosome 
misegregation. Consistent with this hypothesis, the coexistence of centrosome 
defects with aneuploidy has been reported in many tumour types including 
pancreatic (Sato at al., 2001), bladder (Jiang et al., 2003), prostate (Pihan et al., 
2001) and breast cancers (Lingle et al., 2002). 
Further, since deregulation of various genes and pathways have been shown to 
lead to centrosome abnormalities and polyploidy, the centrosome could function 
as a surrogate marker for genomic instability in cancer. The association of 
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centrosome amplification with advanced stage malignancies, recurrent tumours, 
and in cell lines that show more aggressive malignant phenotypes in animal 
models suggest that centrosome defects may be helpful in predicting patient 
prognosis (D'Assoro et al., 2002). 
1.5.3 Telomeric attrition 
Telomeres are specialized DNA-protein structures located at the end of linear 
chromosomes. In mammalian cells, the telomeric sequence is a repetition of a 
hexanucleotide motif, TTAGGG, synthesized by the enzyme, telomerase. 
Telomerase consists of a catalytic reverse transcriptase (TERT) that 
synthesizes telomeres using an RNA template encoded by the telomerase RNA 
component (TERC) gene. Telomeric attrition is defined as the shortening of 
telomeres with each cell division and it occurs due to the inability of DNA 
polymerases to complete the synthesis of chromosome ends, which in normal 
cells ultimately leads to senescence and cell death (Campisi of al., 2001). 
However, in cells with inactivated growth inhibitory pathways, continued 
proliferation causes further telomere erosion and surviving cells emerge by 
activating telomere maintenance mechanisms; the most common being the 
reactivation of telomerase (Artandi and DePinho, 2000; Maser and DePinho, 
2002). 
Telomere length abnormalities detected in precursor lesions of a variety of 
cancers suggests that telomere dysfunction is an early event in carcinogenesis 
(Meeker of al., 2004). Loss of telomere capping proteins forces the telomere to 
become a substrate for end-to-end chromosome fusion and exonucleolytic 
degradation leading to formation of dicentric chromosomes and breakage- 
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fusion-bridge cycles (de Lange, 2002). Furthermore, the high level of anaphase 
bridges (Rudolph et al., 2001), nuclear blebs, chromatin strings and micronuclei 
(Gisselsson et al., 2001b), dicentric chromosomes (Gisselsson at a/., 2001a; 
2002) and chromosomal amplification and deletions (O'Hagan at al., 2002) 
observed in tumours and cell lines with dysfunctional telomeres suggests that 
telomere dysfunction may play a part in CIN. 
1.6 IN VITRO MODELS OF CIN 
Although CIN is prevalent in cancers, the lack of an in vitro model to study CIN 
and its contribution to cancer hinders our understanding of the underlying 
mechanisms involved. Since CIN has been postulated to be induced by 
chemical carcinogens, many studies have used chemicals such as 
nitrosomethylurea (Fabarius et al., 2002), aromatic polycyclic hydrocarbons (Li 
et al., 1997) and bulky adduct forming agents (Bardelli et al., 2001) to induce 
aneuploidy and neoplastic transformation in vitro. However, these studies were 
invariably carried out using rodent and/or carcinoma cell lines that are naturally 
more unstable and prone to transformation. Recently, Bardelli et al. (2001) 
induced CIN in a colorectal cancer cell line using the bulky adduct forming 
agent, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). The presence 
of CIN was detected after 25-50 populations doubling by FISH analysis, using a 
combination of centromeric and telomeric probes to chromosome 12. However, 
the CIN status was estimated at a static time point, which may not reflect the 
presence of the dynamic karyotypic changes associated with CIN and again the 
experiment was carried out using carcinoma cells. The use of normal cells in 
similar experiments might more accurately represent the induction of CIN in 
normal or preneoplastic cells. 
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1.7 ORAL CANCER 
1.7.1 Pathology 
The term oral cancer, according to the International Classification of Disease 
(ICD), version 9, encompasses lip, tongue, mouth, oropharynx, hypopharynx 
and ill-defined sites within lip, oral cavity and pharynx but excludes nasopharynx 
and salivary glands (Cancer Research Campaign, 2000). The majority of oral 
malignancies (>90%) are squamous cell carcinomas of the lining mucosa. 
Oral cancer is an important disease of the developing world with the highest 
rates being reported in South Asia (Parkin et al., 1999). For example, in India, 
oral cancer is the most common cancer and may cause up to 50% of all new 
cases of cancer. By contrast, in Europe and the United States, oral cancer is 
less prevalent and accounts for only 1%-9% of all new cases of cancer (Cancer 
Research Campaign, 2000). Significantly, the disease is associated with high 
rates of morbidity and mortality; typically only 50% of those diagnosed with oral 
cancer will be alive after a period of five years. The mortality rates associated 
with oral cancer have not improved in the last 20 years (Lippman and Hong, 
2001). 
Oral cancer is associated with multiple risk factors, the two most important 
being tobacco usage and alcohol consumption, which are thought to be 
responsible for 75%-95% of all oral cancer cases. Worldwide, the most common 
form of tobacco use is smoking, however, tobacco chewed in the form of betel- 
quid is an important aetiological factor in South East Asia. Alcohol is often 
regarded as a co-carcinogen and is known to act synergistically with concurrent 
tobacco use. Other risk factors include dietary deficiencies, viral infections of 
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the oral cavity (Cancer Research Campaign, 2000) and the differing capacity of 
individuals to metabolise the carcinogens found in tobacco and alcohol (Harty et 
a/., 1997; Schwartz et al., 2001; Buch et al., 2002). 
1.7.2 Oral premalignant lesions 
In oral cancer, the initial presence of a premalignant lesion subsequently 
developing into cancer is well recognised. The two major types of oral 
premalignant lesions are erythroplakia and leukoplakia. Erythroplakia is defined 
as "a fiery red patch that cannot be characterised clinically or pathologically as 
any other definable disease" and leukoplakia as "a predominantly white lesion 
of the oral mucosa that cannot be characterised as any other definable lesion" 
(Crissman and Sakr, 2001). Leukoplakias can be further divided into 
homogeneous, predominantly white lesions and non-homogeneous or speckled 
lesions, which contain a mixture of white and red areas (Crissman and Sakr, 
2001). 
Erythroplakia is a rare lesion and is usually the clinical manifestation of either 
severe dysplasia or carcinoma. Leukoplakias are more common lesions and 
have variable rates of malignant transformation; the estimated rate of 
transformation is approximately 6% over a 10-year period. When histologically 
dysplastic lesions are considered as a group, the estimated rate of 
transformation, however, increases to between 16-36% (Wamakulasuriya, 
2000). Furthermore, there is evidence that some white patches can develop 
cancer in the absence of pre-existing epithelial dysplasia and some with 
dysplasia may even regress (Mao, 1997, Reibel, 2003). 
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In the West, only a loose association exists between oral premalignant lesions 
and subsequent carcinoma development. However, in South East Asia, 
premalignant lesions commonly precede oral carcinomas. Currently, the limited 
ability to identify lesions that have the greatest malignant potential poses a 
great challenge in targeting patients for treatment (Reibel, 2003). 
1.7.3 Molecular pathology of oral cancer 
Frequent genetic alterations of genes in oral cancer suggest that these events 
are important in the development of oral cancer. Some of the most commonly 
altered chromosomal regions in oral cancer includes 3p, 9p21-22,11g13 and 
17p13 (Scully et al., 2000; Kim and Califano, 2004) 
Loss of heterozygosity (LOH) at chromosome 3p has been identified in 
approximately 60% of oral carcinomas (Califano of al., 1996). Some of the 
putative tumour suppressor genes identified at 3q include the fragile histidine 
triad (FHIT) gene and RASSFIA. Hypermethylation of these genes have been 
reported in a variety of cancers but their involvement and their role in oral 
cancer, however, is unclear (Scully of al., 2000; Kim and Califano, 2004). 
Amongst the various putative tumour-suppressors located at 9p21-22, alteration 
of the CDKN2A locus that encodes for p16"11" ' and p14ARF has assumed 
considerable importance. Genetic alteration of p16'NK4'4 is the most common 
abnormality in oral cancer (Kim and Califano, 2004) and approximately 90% of 
OSCCs exhibit lack of p161NK4' expression (Wu et a/., 1999). p16INK'4A is a Cdk 
inhibitor, which functions in the retinoblastoma (Rb)/E2F pathway. Inactivation 
of p16INK4A results in deregulation of the Rb pathway and inappropriate cell 
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cycling. Alteration of p14i4RF has also been reported to occur concomitant with 
p16hNºc4A inactivation in oral cancer (Shintani of al., 2001). p14ARF functions to 
modulate MDM2-mediated degradation of p53 (Nevins, 2001), loss of which 
might result in deregulated cell cycle arrest and apoptosis. 
Amongst the many genes harboured within the 11q13 region, Cyclin D1 is 
frequently altered in oral cancer. Cyclin D1 amplification and protein 
overexpression has been shown to occur in oral cancer (Rousseau et al., 2001). 
Cyclin D1 regulates the phosphorylation of Rb through binding with Cdk4 or Cdk 
6 of the Rb pathway. Concomitant amplification of Cyclin D1 with inactivation of 
p16INK4A has been suggested to confer additional advantage to tumour cells 
(Okami et al., 1999). 
The p53 gene, which is located at 17p13 is one of the most frequently mutated 
gene in all human malignancies and is mutated in up to 50% of oral cancers 
(Paterson at a!., 1996). p53 is a critical modulator of the cellular response to 
various stresses. Loss of p53 is thought to occur late in oral cancer (Murti at a!., 
1998) and is associated with transformation to the invasive phenotype 
(Shanavaz et a!., 2000). Mutations within the DNA binding surface region of p53 
have been reported to be associated with aggressive tendency within tumours 
and worsened clinical outcome (Yamazaki at a!., 2003). 
1.7.4 Markers of malignant development in oral precursor lesions 
The estimation of the malignant potential of oral precursor lesions is currently 
based on histologic assessment of the presence and degree of epithelial 
dysplasia, which is graded as mild, moderate or severe. This technique is, 
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however, highly subjective and frequently lacks agreement between observers 
(Sudbo et al., 2001c). Consequently, reliable biomarkers of malignant 
transformation are actively being sought. For example, loss of heterozygosity 
(LOH) at selected chromosome regions, defects in p53 and aneuploid status 
have been evaluated for their ability to predict malignant change in oral 
premalignant lesions. 
1.7.4.1 Loss of heterozygosity (LOH) 
LOH resulting from loss of genomic material from one of a pair of 
chromosomes, assessed using microsatellite markers to short tandem repeats 
of DNA sequences, has frequently been used to predict malignant development. 
For example, the presence of LOH at 3p14 and/or 9p21 in oral leukoplakias was 
shown to carry a higher risk of malignant progression (Mao et al., 1996). Later, 
based on identical allelic loss between premalignant lesions and cancer and 
additional LOH analysis, a linear progression model was developed for oral 
cancer, whereby retention of 3p and/or 9p is associated with low risk of 
progression, LOH at 3p and/or 9p is associated with intermediate risk of 
progression and LOH at 3p and 9p accompanied by additional LOH at 4q, 8p, 
11 q, 13q or 17p have a high risk of malignant progression (Califano at al., 1996; 
Rosin at al., 2000). The overall accumulation of genetic defects rather than the 
order in which they occur has been suggested to be critical for oral cancer 
development (Califano et al., 1996; Partridge et al., 1998; Jiang et al., 2001) 
The use of LOH to predict malignant progression, however, is limited because 
only selected microsatellite loci are examined, which might be unsuitable for 
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analysis of lesions with LOH at different sites. Further, the assessment of 
multiple markers is both time consuming and expensive. In addition, evidence of 
the polyclonal nature of cancer, possibly due to the field cancerization effect of 
the oral mucosa (Jang et al., 2001; Ai at al., 2001; Partridge et al., 1997), 
suggests that malignant progression might not occur in a linear fashion as 
previously suggested (Shahnavaz et al., 2001). A long-term study of cancer risk 
assessment in oral premalignant lesions, however, indicates that LOH at 
chromosome 3p or 9p is predictive when used in conjunction with other 
biomarkers such as chromosome polysomy and p53 expression along with 
histopathological parameters and the prior cancer history of the patient (Lee et 
al., 2000) 
1.7.4.2 p53 
p53 protein is activated and stabilized in response to cellular stress and then 
functions as a transcription factor for genes involved in inducing either cell cycle 
arrest or cell death (Vogelstein et al., 2001). p53 is usually not detected in 
normal cells, whilst mutant p53 protein has a prolonged half-life and, therefore, 
can be detected by immuno-staining techniques. 
Recent evidence suggests that suprabasal expression of p53 in dysplastic 
lesions (Cruz et al., 1998) and non-malignant mucosa at the resection margin of 
carcinomas (Cruz et al., 2000) could predict carcinoma development and 
recurrence, respectively. However, other studies have indicated that mutation of 
p53 is a late event in oral carcinogenesis (Murti et al., 1998; Shanavaz et al., 
2000) and, therefore, may be unsuitable as a marker of malignant progression. 
Furthermore, inconsistencies between mutations in p53 and 
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immunohistochemical detection of the mutant protein (Shanavaz at al., 2000; 
Kuo at al., 1999), and involvement of other p53 inactivating mechanisms such 
as overexpression of MDM2 (Carroll et al., 1999), loss of p14n (Bradley at al., 
2001) and interaction with viral proteins (Gasco and Crook, 2003), could result 
in false interpretation of results. p53 status, therefore, is unlikely to be a reliable 
predictor of malignant transformation (Wamakulasuriya, 2000). 
1.7.4.3 Aneuploid status 
Genomic instability reflects the propensity and susceptibility of the genome to 
acquire multiple alterations resulting in an altered DNA content or aneuploidy. 
Chromosomal abnormalities are frequently encountered in both premalignant 
and malignant lesions of the oral cavity (Weber et al., 1998) and have been 
demonstrated in oral carcinoma cell lines (Okafuji et al., 1999, Hermsen et al., 
1997). One study has showed that aneuploidy can occur even in 
morphologically normal oral mucosa suggesting that genomic instability occurs 
early in oral cancer and precedes morphological changes (Ai et al., 2001). 
Furthermore, genomic instability could potentially provide the tumour cells with 
a significant growth advantage through incidental alterations of bystander genes 
that might not be related to malignant progression (Masayesva et al., 2004). 
The hallmark study by Sudbo and colleagues (Sudbo et a/., 2001 a) showed the 
importance of genomic instability in the pathogenesis of oral cancer by 
demonstrating the diagnostic potential of altered DNA content in oral 
premalignant lesions. This study used the DNA ploidy status of oral dysplasias 
to predict malignant progression. A total of 150 oral dysplastic leukoplakias, 
from patients who were followed for a mean of 8.6 years, were investigated with 
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respect to DNA content. Only 3/105 diploid cases (3%) as opposed to 21/25 
aneuploid (84%) progressed to carcinoma during follow-up. The cumulative 
disease free survival rates of diploid, tetraploid and aneuploid groups were 
97%, 40% and 16%, respectively. The reliability of DNA ploidy assessment in 
predicting malignant progression was further strengthened following the 
successful prediction of oral erythroplakias in a majority of patients (92%), 
which is consistent with the high tendency of these lesions to progress. Most 
significantly, aneuploidy was also shown to reliably predict malignant 
progression of non-dysplastic lesions (Sudbo et al., 2001 b). Subsequently, 
Sudbo et al. (2004) reviewed their original 150 patients over a 3-year period and 
demonstrated that complete resection of oral leukoplakia does not prevent 
progression to carcinoma and further, oral carcinoma arising from aneuploid 
leukoplakia demonstrates aggressive clinical behaviour associated with 
advanced stage and poor survival in comparison to tetraploid or diploid lesions. 
Taken together, these studies suggest that aneuploidy is an excellent marker of 
malignant progression in oral premalignant disease. Little is known, however, 
about the mechanisms responsible for aneuploidy in oral cancer. Knowledge of 
these mechanisms would greatly enhance our understanding of the molecular 
biology of the disease and might identify specific genetic markers of malignant 
progression. 
1.8 GENERAL AIMS 
CIN or aneuploidy, characterised by an altered DNA content and the presence 
of structural and numerical chromosomal aberrations, has been suggested to 
drive cancer progression by unbalancing the gene dosage of tumour suppressor 
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genes and oncogenes. Aneuploidy has been shown to occur early in oral 
cancer and is a reliable predictor of malignant progression in a variety of oral 
premalignant lesions. There is a paucity of information, however, regarding the 
mechanisms underlying CIN in oral cancer. 
Previous cytogenetic characterization of a series of human oral squamous cell 
carcinoma (OSCC)-derived cell lines established in the Experimental Pathology 
Group at the University of Bristol revealed that the cells exhibited consistent 
chromosomal rearrangements and altered chromosome numbers, indicating 
that the cell lines were aneuploid (Patel et a/., 1993). These cell lines, therefore, 
represent valuable tools to investigate the underlying mechanisms of CIN in oral 
cancer. The MIN status of these cell lines has not been examined and, 
therefore, the present study first examined the expression of the hMLH1 and 
hMSH2 genes to confirm that that cell lines did not exhibit MIN. Due to the 
chromosome alterations in the OSCC-derived cell lines, defects in the 
chromosome segregation machineries such as the mitotic and tetraploidy 
checkpoints and the centrosomes were investigated. 
During the course of this work, it was determined that centrosomal 
abnormalities occur frequently in OSCC-derived cell lines suggesting that 
centrosome defects may underlie CIN in oral cancer. The study was extended 
to analyse the status of the centrosomes in oral tissues with a view to 
determining whether centrosome abnormalities were associated with a 
malignant phenotype and progression. 
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In a parallel investigation, immortalised human normal oral keratinocyte cells 
were treated with the carcinogen PhIP in an attempt to develop an in vitro 
model of CIN. Having determined that induction of PhIP resistance resulted in 
consistent chromosomal abnormalities only and not a dynamic CIN, we aimed 
to determine if the induction of PhIP resistance could have produced cells that 
were resistant to other forms of DNA damage. 
1.9 HYPOTHESIS 
This study tested the hypothesis that defects in the chromosome segregation 
machinery are responsible for the CIN observed in oral cancer and that this 
process can be recapitulated in human immortalised normal oral keratinocytes 
in vitro. 
1.10 OBJECTIVES 
1. To analyse the fidelity of the mitotic checkpoint in a series of human oral- 
SCC cell lines. 
2. To analyse centrosome physiology and function in a series of human 
oral-SCC cell lines. 
3. To analyse centrosome abnormalities in archival paraffin-embedded oral 
dysplasias and SCCs 
4. To develop an in vitro model of CIN using an immortalised human normal 
oral keratinocyte treated with the carcinogen PhIP. 
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Figure 1.1 A two-stage model for how carcinogens may cause cancer 
via aneuploidy. 
In the first stage, a carcinogen "initiates" carcinogenesis by generating an 
aneuploid, preneoplastic cell. The process will also generate cells with 
nonviable chromosome combinations. In the second stage, the destabilization 
of the karyotype and the chromosome segregation machineries by the induction 
of aneuploidy, in turn, drives the autocatalytic evolution of the preneoplastic and 
its progeny cells to generate cells with new karyotypes capable of tumour 
progression. The autocatalytic karyotype evolution and the low probability of 
generating a viable karyotype by chance that can outperform normal cells would 
also explain the previously unresolved, carcinogen-independent transformation 
of a preneoplastic into a neoplastic cell and the notorious long latent periods 






Figure 1.2 The centrosome duplication cycle in animal cells. 
The centrosome is composed of a pair of perpendicularly oriented centrioles. 
(0.2µm in diameter and 0.2-0.5µm in length) composed of nine identical and 
equally spaced microtubule arrays. Centrosome duplication is initiated at the 
late G1/early S phase of the cell cycle by the splitting of the centriolar pair. This 
is followed by the formation of procentrioles (blue) in the vicinity of the parental 
centrioles (red); the procentrioles continue to elongate during S and G2. At the 
end of G2, the new pair of mature centrosomes migrate to opposite poles of the 
cell to form bipolar spindles. 
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Figure 1.3 Defects in cell division as a major route to numerical 
centrosome aberrations and aneuploidy. 
According to this model, tetraploidization (rather than enhanced centrosome 
duplication) is a prevalent cause for numerical centrosome aberrations. A 
number of errors could lead to an abortive mitotic exit, generating cells with 
tetraploid DNA and two pairs of centrosomes. A p53 wild type cell will be 
arrested in Gi and/or eliminated. In the absence of a functional p53, however, 
cells will progress through an extra round of DNA replication and centrosome 
duplication, giving rise to cells with four pairs of centrosome, which during 




MATERIALS AND METHODS 
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2.1 CELL LINES 
2.1.1 OSCC-derived cell lines 
Seven human oral squamous cell carcinoma (SCC) cell lines (H103, H157, 
H314, H357, H376, H400, H413) established in the Division of Oral Medicine, 
Pathology and Microbiology, University of Bristol, were used in the present 
study. Details of the methods by which the tumour-derived cell lines were 
established, including the prevention of infection and 3T3 fibroblast support, 
have been described previously (Prime et al., 1990). Briefly, tissues were 
collected from fresh surgical biopsies of untreated human oral squamous cell 
carcinomas. The tissues were divided and half was used for cell culture and the 
remaining half was fixed in 10% (v/v) formol saline prior to histological 
examination. Tumours were classified clinically with regard to the site (S), 
tumour size (T), lymph node involvement (N), metastatic spread (M) and 
pathological grade of the tumour (P). The tumours were staged according to the 
STNMP system (Langdon, 1995; Table 2.1). 
The cells have been characterised with regard to chromosomal anomalies 
(Patel et a/., 1993), Ha-ras, p53 and p16 mutations (Yeudall et a/., 1993; 1995, 
Wu et a/., 1999) and tumorigenicity following orthotopic transplantation to the 
floor of the mouth in athymic (Balb/C; nu/nu) mice (Prime et a/., 2004). The 
characteristics of the human oral carcinoma cell lines are summarised in Table 
2.2. 
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2.1.2 Normal and immortalised human oral keratinocytes 
Normal human oral keratinocyte cultures were established from excess tissue 
originating from routine oral surgical procedures. Although different primary 
cultures of normal keratinocytes were used in individual experiments they were 
assumed to behave similarly. The Swiss mouse embryo fibroblast cell line 3T3 
(European Collection of Animal Cell Cultures, UK) was used in the culture of 
normal oral keratinocytes in order to assist their growth and to limit host 
fibroblast contamination 
OKF6/TERT-1, an oral mucosal keratinocyte cell line immortalised via the 
retroviral transduction of the human telomerase reverse transcriptase (hTERT), 
was obtained from Dr J. Rheinwald. (Harvard Institute of Medicine, Boston, 
USA). OKF6/TERT-1 has a heterozygous deletion involving all three exons of 
p16lNK4a and has a wild type p53 (Dickson et al., 2000). 
2.1.3 Control cell lines 
Two colorectal cell lines, HCT116 and CaCo2, were used as controls in this 
study. HCT116, a mismatch repair deficient (Bardelli et a/., 2001), diploid 
human colorectal carcinoma cell line carrying wild type p53, was obtained from 
Dr. B. Vogelstein (School of Medicine, John Hopkins University; Chan et al., 
2000). Caco2, which contains hyperamplified centrosomes, was obtained from 
Dr. C. Paraskeva (Department of Microbiology and Pathology, University of 
Bristol; Ghadimi et al., 2000). 
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2.2 TISSUES 
Formalin-fixed paraffin embedded tissues were obtained from the Department 
of Histopathology, Bristol Royal Infirmary of the United Bristol Healthcare Trust 
(UBHT). Approval from the UBHT Research Ethics Committee was obtained 
prior to commencing the study. 
2.3 MATERIALS 
For all techniques, unless otherwise stated, chemicals were of molecular 
biology or Analar grade and were obtained from Sigma (UK), BDH (UK), Difco, 
Merck or ICN. Restriction enzymes were obtained from Promega (UK). All cell 
culture and associated procedures were carried out in a MDH laminar flow 
cabinet (Microflow Ltd., UK) and cell culture medium and supplements were 
obtained from Invitrogen (UK). Cell culture plastics were obtained from Iwaki 
(UK), while plastics for other purposes, such as molecular biology, were 
obtained from Greiner (UK) and Corning (UK). The commercial suppliers are 
listed in Appendix 1. 
2.4 CELL CULTURE TECHNIQUES 
2.4.1 3T3 feeder cells 
1x105 3T3 fibroblasts were cultured in 90 mm culture dishes containing 10 ml 
Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) foetal 
bovine serum (FBS) and 0.6 pg/ml L-glutamine (fibroblast medium). Cells were 
incubated for 7 days in a humidified atmosphere of 95% air/5% CO2 at 37°C. 
Confluent cultures of 3T3 fibroblasts were used as feeder cells for normal 
keratinocyte cultures (Rheinwald and Beckett, 1981). Prior to use, 3T3s were 
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treated with a final concentration of 10 pg/ml mitomycin C for 2 hours at 37°C 
and, after cell number determination, 2x105 cells were seeded into 25 cm2 flask 
containing normal human oral keratinocytes. 
2.4.2 Primary culture of normal oral keratinocytes 
Primary cultures of human normal oral keratinocytes were established by single 
cell suspension. Excess tissue originating from routine oral surgical procedures 
was transported to the laboratory in Dulbecco's modified Eagle's medium 
(DMEM)/F12 (1: 1) containing 10% (v/v) foetal bovine serum (FBS), 0.6 pg/ml L- 
glutamine, 0.5 pg/ml hydrocortisone (epithelial medium) supplemented with 10 
ng/ml cholera toxin, 200 IU/ml penicillin, 200 pg/ml streptomycin and 5 pg/ml 
fungizone. The tissues were washed twice in sterile PBS containing 200 IU/ml 
penicillin and 200 pg/ml streptomycin, immersed briefly in absolute ethanol and 
rinsed thoroughly in PBS to remove surface contaminants. The tissue was then 
cut into fine pieces and incubated in 2 ml of 0.025% (w/v) type III trypsin 
containing 200 IU/ml penicillin, 200 pg/ml streptomycin and 5 pg/ml fungizone, 
at 4°C for 12 hours. Following overnight incubation, most of the trypsin was 
discarded and the tissues incubated in the residual trypsin solution at 37°C for 1 
hour. The trypsin was then neutralised by the addition of 5 ml of epithelial 
medium, containing antibiotics and anti-fungals, and the epithelial cells were 
detached by vigorous pipetting. The supernatant containing the epithelial cells 
was centrifuged (60g, 10 minutes) and the pellet resuspended in epithelial 
medium containing 10 ng/ml cholera toxin, 0.04 IU/ml insulin, I µg/ml 
transferrin. 5x105 keratinocytes were seeded together with 2x105 of mitomycin 
35 
C treated mouse 3T3 fibroblast (Section 2.4.1) into a 25 cm2 flask and 
incubated at 37°C in a humidified atmosphere of 95% air/5% CO2. 
Primary oral keratinocytes were also grown in keratinocyte serum free medium 
(KSFM; Section 2.4.3.3). Normal keratinocytes grown in KSFM medium do not 
require mitomycin C treated 3T3 fibroblast cells to support growth. 
2.4.3 Maintenance of cultured cells 
2.4.3.1 Normal oral keratinocytes 
Newly established primary cultures of normal oral keratinocytes were left 
undisturbed for 4 days to allow cell attachment to the culture flask. 
Subsequently, the culture medium was replaced every 2-4 days depending 
upon the growth rate of the cells. The fresh epithelial medium was 
supplemented with 5 ng/ml epidermal growth factor (EGF) to stimulate growth. 
Host fibroblasts and 3T3 fibroblasts were removed from keratinocyte cultures 
prior to experiments by washing the cells with PBS and incubating them in 
0.02% (w/v) ethylene diamine tetra-acetic acid (EDTA) solution in PBS for 30-60 
seconds at room temperature. An equal volume of PBS was added and the 
solution was pipetted over the cells for 60 seconds. The solution was removed 
and the cells were washed with PBS. Complete removal of host fibroblast was 
determined microscopically. Cells were normally discarded after the second or 
third passage when they showed signs of senescence. 
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2.4.3.2 Tumour-derived epithelial cell lines 
Tumour-derived epithelial cell lines were cultured in Dulbecco's modified 
Eagle's medium (DMEM)/F12 (1: 1) containing 10% (v/v) foetal bovine serum 
(FBS), 0.6 pg/ml L-glutamine, 0.5 pg/ml hydrocortisone and 1 mg/ml cholera 
toxin (epithelial medium) and were grown in a humidified atmosphere of 95% 
air/5% CO2 at 37°C. The culture medium was replaced every 3-4 days. CaCo2 
cells were cultured in DMEM medium containing 10% FBS, 0.6 µg/ml L- 
Glutamine and 0.5 pg/ml hydrocortisone. 
2.4.3.3 Immortalised normal oral cells 
The OKF6-TERT/1 cell line was grown in keratinocyte serum-free medium 
(KSFM; Invitrogen) containing 25 µg/ml bovine pituitary extract, 0.4 ng/ml 
epidermal growth factor (EGF) [diluted in 20 mM HEPES-buffered Earle's salt, 
0.1% bovine serum albumin (BSA)] and the calcium chloride (CaCl2) 
concentration increased to 0.4 mM (Dickson et al., 2000). The culture medium 
was replaced every 2 days. 
2.4.4 Sub-culture and cell number determination 
Cells were sub-cultured every 7-10 days when -90% confluent. The culture 
medium was discarded and the cultures were washed with PBS. The cells were 
enzymatically detached by incubating in 0.025% (v/v) trypsin / 0.01% (w/v) 
EDTA solution in PBS for 5-30 minutes at 37°C. The trysin/EDTA solution was 
neutralised by the addition of an equal volume of epithelial medium and the cell 
suspension was centrifuged (60g, 10 minutes). The cell pellet was resuspended 
in 5 ml of culture medium. Cell number was determined using Coulter counter 
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(Coulter Z Series, Coulter Corporation, USA). Cells were re-seeded at 5x105 
cells per 75 cm2 flask in epithelial medium and maintained in culture, as 
previously described. 
For the immortalised normal oral keratinocyte cell line, OKF6/TERT-1, cells 
were sub-cultured every 5 days, when about 30% confluent. The KSFM medium 
has been designed to support low density and clonal growth of cells and does 
not contain levels of nutrients and growth factors that are required to maintain 
keratinocytes in a healthy proliferative state at high densities. Cells were 
harvested as described above for the tumour-derived oral cell lines. The cell 
pellet was resuspended in KSFM medium and the cells re-seeded at 1x105 cells 
per 75 cm2 flask and maintained in culture as previously described. 
2.4.5 Storage and retrieval of cell 
Stocks of epithelial cells were maintained in liquid N2. After determination of the 
cell number, 5x105 - 1x106 cells were re-suspended in epithelial medium with 
20% (v/v) FBS and 10% (v/v) dimethylsuiphoxide (DMSO) and then transferred 
into cryovials. The cells were placed in a -70°C freezer for 12-24 hours before 
being transferred to liquid N2 at -196°C for long-term storage. 
To cryopreserve OKF6-TERT/1 cells, an equal volume of chilled epithelial 
medium containing 20% (v/v) FBS and 20% (v/v) DMSO was added to cells 
suspended in KSFM medium, prior to freezing as described above. 
Cells were recovered from storage in liquid N2 by rapid thawing of the cryovials 
in a water bath at 37°C. The cells were then transferred into 10 ml of epithelial 
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medium and centrifuged (60g, 10 minutes). The supernatant was discarded, the 
cell pellet resuspended in epithelial medium for tumour-derived cell lines or 
KSFM medium for the OKF6/TERT-1 cell line and the suspension transferred to 
a 75 cm2 tissue culture flask. The cells were maintained in culture, as previously 
described (Section 2.4.3). 
2.4.6 Microscopy 
Cell cultures were examined with an Olympus IMT-2 (UK) inverted phase 
contrast microscope. Photomicrographs of the cultured cells were taken with an 
Orthomat camera attached to the inverted phase contrast microscope. 
Photomicrographs were printed on Kodak polycontrast paper (Kodak, UK). 
2.4.7 Mycoplasma testing and treatment 
Cell cultures were examined routinely for mycoplasma contamination using the 
Hoescht fluorescent staining technique (Chen, 1977). The cells were grown on 
sterile glass coverslips in 60 mm dishes with culture medium lacking antibiotics 
and G418. After 10 days without a change of medium, the cells were fixed by 
the addition of glacial acetic acid/methanol fixative (1: 1) for 2 minutes. The 
fixative was removed and replaced with another 5 ml fixative for 5 minutes and 
this step was repeated. Following aspiration of the fixative, the cells were air 
dried for 10 minutes at room temperature. The Hoescht No 33258 stain (Sigma, 
UK) stock solution [0.05% (w/v) in ddH2O] was diluted 1: 500 in PBS and added 
to the cells for 10 minutes at room temperature. After removal of the stain, the 
cells were washed twice with PBS and the coverslips mounted in PBS/glycerol 
(1: 9). Stained cells were examined under ultraviolet light at 340nm using a Leitz 
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Ortholux microscope (Leica, UK) with a UGI filter, a BG38 suppression filter, a 
blue filter and a x40 objective. Mycoplasma contamination was indicated by the 
presence of speckled perinuclear fluorescence. Cells, which were found to be 
myocoplasma positive by Hoescht staining, were treated with mycoplasma 
removal agent (MRA; ICN Pharmaceuticals, UK). Cells were incubated with 10 
µl MRA per ml culture medium for 7 days at 37°C and then re-tested using the 
Hoescht stain. 
2.4.8 Transfection of cell lines 
Cells were transfected using the Fugene 6 Reagent (Roche, UK). To prepare 
the transfection mixture, 30 µl Fugene 6 was added to 100 µl of epithelial 
medium without FBS (serum-free medium) in an eppendorf tube and mixed. 
The mixture was left for 5 minutes at room temperature. The Fugene-medium 
mixture was then transferred into an eppendorf tube containing 10 µg plasmid 
DNA, mixed and left for 15 minutes at room temperature. 
For transfection, cells were grown to 30-50% confluence in 60mm dishes. The 
culture medium was removed and the cells were washed twice in serum-free 
medium and 100 µl of Fugene/DNA mixture was added to each culture dish 
containing 1.8 ml epithelial medium. The cells were incubated in a humidified 
atmosphere of 95% air/5% CO2 at 37°C overnight, after which the culture 
medium was replaced with 5 ml epithelial medium and the cells were cultured 
for a further 48 hours. The cells were then harvested through trypsinization as 
previously described (Section 2.4.4) and sub-cultured into 75 cm2 flasks in 
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epithelial medium containing 600 µg/ml geneticin sulphate (G418) in order to 
select for stable transfectants. 
2.4.9 Cell cloning of transfectants 
1x 103 cells per dish were seeded into 100 mm dishes and cultured until 
islands of approximately 1000 cells per colony were observed. Small islands of 
cells were selected which had proliferated from single cells and which were at a 
distance from other cells. The medium was aspirated and the cells were 
washed with PBS. Cloning rings were coated on their base with sterile Vaseline 
and were placed over the chosen cell islands; the placement of the rings was 
checked microscopically before selective enzymatic detachment of the cells 
within the rings. Trypsin/EDTA was pipetted into the rings and incubated for 20 
minutes at 37°C. The cells were then removed to 6-well plates containing 
medium supplemented with G418. Cells were grown to confluence before 
transfer to 75 cm2 tissue culture flasks. 
2.4.10 Irradiation of cell cultures 
Cells were grown to approximately 40% confluence in a 25 cm2 flask. Prior to 
irradiation, the medium was replaced with fresh medium containing 4.5 mM 
Hepes buffer. The cells were irradiated using a RX30/55 irradiator (Gravatom 
Industries) with a total dose of 5Gy using a Caesium 137 source (Amersham). 
Following irradiation, the medium was replaced and the cells incubated at 37°C 
as required. 
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2.4.11 MTT assay 
3-[4,5-Dimethylthiazol-2y1]-2,5-diphenyltetrazolium bromide; thiazolyl blue 
(MTT) (Sigma) was made up as a5 mg/ml stock in warm serum free medium 
and left in the dark for 20 minutes to dissolve. The solution was filter sterilised 
using a 0.2 µm filter and diluted in KSFM medium to give a1 mg/ml solution. 
The medium was aspirated from the wells and 1 ml of the MTT solution added 
to each well and incubated for 1 hour. The MTT solution was removed, the cells 
rinsed with PBS and the resulting water-insoluble formazan salt, created by the 
metabolic activity of viable cells, was dissolved using 1 ml/well DMSO. The 
absorbance of the salt solution at 520 nm was determined with DMSO as a 
blank. 
2.4.12 Assessment of apoptosis 
Cells were harvested using accutase (PAA Laboratories) in place of trypsin, as 
described in section 2.4.4. Accutase combines protease and collagenolytic 
activities for gentle detachment of adherent cells for the study of cell surface 
markers via FACS. The cell pellet obtained following centrifugation was 
resuspended in 200 µl cold binding buffer (10 mM Hepes [pH 7.4], 140 mM 
NaCl2,5 mM CaCI2) containing 4 µl Annexin V-FITC (Alexis) for every 1x106 
cells. Cells were incubated in the dark at room temperature for 10 minutes. 
Additional binding buffer was added to the cells and centrifuged (60g, 10 
minutes, room temperature). The cell pellet was resuspended in 400 µl binding 
buffer containing 2 µg/ml propidium iodide and FACS analysis was performed 
on a FACScan (Becton Dickinson) within an hour of processing the cells. 
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Controls included unstained cells and cells stained individually with annexin V- 
FITC or Pl. 
2.5 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
Following cell number determination, cells were centrifuged (60g, 10 minutes, 
room temperature), washed with PBS and resuspended in fresh ice cold 70% 
ethanol to yield a final concentration of 1x106 cells /ml. The fixed cells were 
stored at -20°C in 1 ml aliquots until needed for FACS analysis. 
Prior to FACS analysis, ethanol fixed cells were centrifuged (60g, 10 minutes, 
room temperature) and resuspended in I ml PBS containing 15 µg/ml RNAse A 
and 20 gg/ml propidium iodide and incubated at 37°C in the dark for 30 minutes 
and stored at 4°C for 24 hours. The cells were syringed to create a single cell 
suspension prior to analysis and 1x104 cells were analysed per sample using 
FACScan (Becton Dickinson) and the data were analysed using the ModFit LT, 
version 2 (Becton Dickinson). 
2.6 CELL CYCLE CHECKPOINT ANALYSES 
2.6.1 Mitotic checkpoint analysis 
Cells were seeded at a density of 1 x106 cell per 75 cm2 flask and incubated for 
24 hours. Cells were then incubated in fresh epithelial medium containing 0.2 
pg/ml nocodazole for 18 hours; cells treated with epithelial medium containing 
DMSO were used as controls. Loosely attached cells were first isolated through 
gentle agitation and adherent cells were harvested by trypsinization, as 
previously described (Section 2.4.4). The cells were pooled, centrifuged (60g, 
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10 minutes, room temperature) and the pellet resuspended in epithelial medium 
and the cells counted. Cell cycle analysis of the harvested cells was performed, 
as previously described (Section 2.5). 
2.6.2 Tetraploidy checkpoint analysis 
Cells were grown to -70% confluence and then treated with 0.04 µg/ml 
nocodazole for 18 hours. Arrested mitotic cells were harvested through 'mitotic 
shakeoff (i. e. gentle knocking of the flask), centrifuged (60g, 10 minutes, room 
temperature) and washed in serum free medium to remove any traces of 
nocodazole. The cells were then incubated in epithelial medium containing 10 
µM dihydrocytochalasin B (DCB; Sigma) for 5 hours. Following DCB treatment, 
the cells were washed in serum free medium to remove traces of DCB and 
incubated in drug free epithelial medium for 18 or 36 hours. Cells were 
harvested, counted (Section 2.4.4) and cell cycle analysis was performed as 
previously described (Section 2.5). 
2.7 IMMUNOFLUORESCENCE 
2.7.1 Centrosome abnormalities in OSCC-derived cell lines 
Cells were seeded at a density of 3x105 cells/coverslip (22 mm), in a 6-well 
plate and allowed to adhere overnight at 37°C. Attached cells were treated with 
permeabilization buffer (45 mM Pipes (pH6.9), 45 mM Hepes, 10 mM EGTA, 
0.1% TritonX-100/PBS) for 5 minutes and fixed in methanol (-20°C) for 10 
minutes, air dried briefly and washed in 0.1% tritonX-100/PBS (pH7.2; PBST). 
Cells were blocked in blocking buffer (1 % normal goat serum, 3% bovine serum 
albumin in PBST) for 30 minutes followed by incubation in primary monoclonal 
44 
mouse anti gamma-tubulin (T6557; Sigma) and polyclonal rabbit anti-pericentrin 
[PRB-432C; Berkley Antibody Company (BabCo, USA)] antibodies at 1: 300 
dilution in blocking buffer, for 1 hour at room temperature in a humidified 
chamber. Cells were washed in PBST and incubated in secondary Cyc 3 
conjugated anti-mouse (1: 500; Jacksons Laboratories) and FITC conjugated 
anti-rabbit antibody (1: 100; Sigma) in PBS (pH7.2), for 1 hour at room 
temperature in a dark humidified chamber. Cells were washed in PBST, air- 
dried and mounted in Vectashield mounting medium with DAPI (Vector 
Laboratories) and stored at 4°C until analysis. 
A minimum of 200 cells was counted for each cell line under a fluorescence 
microscope to determine the percentage of cells with centrosomal 
abnormalities. Images of centrosomes were obtained using the Inverted Leica 
Confocal Imaging Spectrophotometer System (TCS-SP2) attached to a Leica 
DMIRBE inverted microscope. The microscope was equipped with a five laser 
configuration, which included an Argon laser (458,476,488,514 nm lines), a 
Green HeNe laser (543 nm lines), a Red HeNe laser (633 nm lines), a UV laser 
(351,364 nm lines) and a 430 nm laser. 
2.7.2 Centrosome abnormalities in paraffin embedded oral archival 
material 
5 pm thick sections were cut from paraffin-embedded archival tissues, mounted 
on polylysine-coated slides (Shandon) and incubated at 37°C overnight. 
Sections were dewaxed in xylene (3 x5 minutes), rehydrated through 100% 
ethanol (3 x2 minutes) and finally in running tap water. Antigen retrieval was 
achieved by microwaving; sections were immersed in I litre of 0.1 M citrate 
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buffer (pH 6.0) and microwaved at 960W for 30 minutes. The sections were 
cooled to room temperature with running tap water and washed in PBS (pH7.2). 
The sections were then incubated with mouse monoclonal anti-gamma tubulin 
antibody (Sigma) and polyclonal rabbit anti-cytokeratin at dilutions of 1: 200 and 
1: 70 respectively, in blocking solution [10% normal goat serum in PBS (pH7.2)] 
for 1 hour at room temperature. The sections were then washed in PBS 
(pH7.2), incubated with secondary Cyc 3 conjugated anti-mouse (Jacksons 
Laboratories) and FITC conjugated anti-rabbit antibodies (Sigma) at dilutions of 
1: 250 and 1: 80 respectively, in PBS (pH7.2), for 1 hour at room temperature in 
a dark humidified chamber. The sections were again washed in PBS, air dried 
and mounted in Vectashield mounting medium containing DAPI. Stained 
sections were stored at 4°C. 
2.7.3 Microtubule nucleation assay 
Cells were seeded at a density of 3x105 cells/coverslip (22 mm) in a 6-well plate 
and allowed to adhere for 24 hours. Cells were then incubated in epithelial 
medium containing 10 µg/ml nocodazole (stock: 5 mg/ml in DMSO) for 2 hours. 
The medium was discarded; the cells washed in PBS and allowed to nucleate 
microtubules for 2 minutes. The cells were then fixed and stained, as described 
in Section 2.7.1, to observe microtubule nucleation by the centrosome. The 
mouse anti-alpha tubulin (Sigma) and rabbit anti-pericentrin primary antibodies 
were used at dilutions 1: 200 and 1: 300, respectively. 
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2.7.4 Mitotic index 
Cells were seeded at a density of 3x105 cells/coverslip (22 mm) in a 6-well plate 
and allowed to adhere for 24 hours. Cells were then incubated in epithelial 
medium containing 0.2 pg/ml nocodazole at 37°C for 6-42 hours. The cells were 
then stained immunocytochemically using anti-phospho histone H3 antibody 
(1: 200; Upstate Biotech), as described (Section 2.7.1). 
2.8 CLONING OF CETN2 
2.8.1 Transformation of competent E. coli with plasmid DNA 
One Shot TOP10 competent E. coli cells (Invitrogen, UK) were used for 
transformation of plasmid DNA. A 50 µl aliquot of One Shot cells was used for 
each ligation. Cells were thawed on ice and 1 µg plasmid DNA or 10 Al ligation 
mixture (Section 2.8.8) was added and the vial was tapped gently to mix. The E. 
co/i/DNA mix was incubated on ice for 30 minutes, heat shocked in a water bath 
at 42°C for exactly 30 seconds and promptly placed on ice for 2 minutes. 250 Al 
room temperature S. O. C medium (supplied with the cells) or LB medium was 
added to the cells and the mixture was incubated for 1 hour at 37°C, with 
constant agitation. 20 µl-200 Al of each transformation were plated on LB/agar 
(1.5%, w/v) plates containing 100 µg/ml ampicillin and incubated overnight at 
37°C. Glycerol stocks of clones containing the correct plasmid construct were 
prepared by adding sterile glycerol to overnight bacterial cultures to a final 




2.8.2 Purification of plasmid DNA 
2.8.2.1 Small-scale 
Transformed E. coli cells were grown on LB agar [1.5% (w/v)] plates containing 
ampicillin (100 µg/ml). Single colonies were isolated and inoculated into 5 ml LB 
medium containing 100 µg/ml ampicillin and incubated on an orbital shaker 
overnight at 37°C. Preparations of plasmids were obtained by the alkaline lysis 
of cells derived from overnight cultures (Sambrook et al., 1989). For small-scale 
preparation of DNA, 1.5 ml of overnight culture was centrifuged in an eppendorf 
tube at 12,000g for 30 seconds. Following removal of the supernatant, the pellet 
was evenly resuspended in 100 µl of Solution I (50 mM glucose; 25 mM Tris- 
HCI, 10 mM EDTA; pH 8.0). 200 µl of freshly prepared Solution II (0.2 M NaOH; 
1% (w/v) SDS) was added and mixed rapidly by inverting the tube and the tube 
placed on ice. Then 150 µl of ice cold Solution III (3 M potassium acetate; 5M 
glacial acetic acid) was added, vortexed and stored on ice for 3-5 minutes. The 
solution was centrifuged (12,000g, 5 minutes, 4°C) and the supernatant 
transferred to a fresh tube. An equal volume of phenol/chloroform/isoamyl 
alcohol (25: 24: 1) was added, mixed by vortexing and centrifuged (12,000g, 5 
minutes, 4°C). The top phase was transferred into a fresh eppendorf tube. The 
plasmid DNA was precipitated by adding 2 volumes of ethanol at room 
temperature, the tube vortexed and left at room temperature for 2 minutes and 
centrifuged (12,000g, 5 minutes, 4°C). The pellet was rinsed with I ml 70% 
ethanol and the supernatant removed following brief centrifugation. The pellet 
was allowed to air dry at room temperature for 10 minutes and dissolved in 
50 µl TE (pH8.0) containing 20 µg/ml RNAase A. DNA was stored at -20°C until 
needed. 
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2.8.2.2 Large scale 
For large-scale preparation of plasmid DNA, 500 ml sterile LB medium 
containing 100 µg/ml ampicillin was inoculated with 200 µl from a previously 
prepared 10 ml culture of E. coli and incubated, with agitation, overnight at 37°C. 
The resultant cell suspension was centrifuged (4,000g, 20 minutes, 4°C), the 
supernatant discarded and the pellet re-suspended in 100 ml ice cold STE 
(0.1 M NaCl; 10 mM Tris-HCI (pH8.0); 1 mM EDTA (pH 8.0)). After further 
centrifugation (4,000g, 20 minutes, 4°C), the pellet was re-suspended in 18 ml 
Solution I followed by the addition of 2 ml of freshly prepared lysozyme solution 
(10 mg/ml in 10 mM Tris-HCI (pH 8.0)). 40 ml freshly made Solution II was 
added to lyse the cells and the solution was mixed by inversion and at room 
temperature for 10 minutes. 20 ml Solution III was added and mixed by 
inversion and incubated on ice for 10 minutes to precipitate the protein. The 
protein was removed by centrifugation (4,000g, 20 minutes, 4°C) and the 
supernatant filtered through cheesecloth and transferred to a 50 ml 
polypropylene tube. 0.6 volumes isopropanol was added to the supernatant and 
the mixture was incubated for 10 minutes at room temperature to precipitate the 
DNA, which was recovered by further centrifugation (4,500g, 15 minutes, room 
temperature). The pellet was washed with 70% (v/v) ethanol at room 
temperature, air dried for 10 minutes at room temperature and then re- 
suspended in 3 ml TE buffer (10 mM Tris-HCL; 1 mM EDTA; pH 8.0). 
The maxipreped DNA was purified by equilibrium centrifugation in Caesium 
chloride (CsCI) - ethidium bromide continuous gradient. 1g of CsCI (ultrapure) 
for every ml of DNA solution was added and mixed gently until the salt is 
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dissolved. 0.8 mg/ml ethidium bromide (EtBr) was added for every 10 ml of 
CsCI/DNA solution and mixed. The solution was centrifuged (4500g, 5 minutes, 
room temperature) and the clear red solution transferred into a Beckman (UK) 
tube and the DNA was purified by centrifugation for 16-22 hours at 65,000 rpm 
in a Beckman Ultracentrifuge (NVT 65 rotor, UK) at 20°C. Under ultraviolet 
(U. V. ) light, two bands were visible within the tube: the higher band was 
contained linear bacterial chromosomal DNA and nicked circular plasmid DNA; 
the lower band contained the closed circular plasmid DNA. The plasmid DNA 
was removed into another Beckman tube using a 19G needle and syringe and 
the CsCI gradient centrifugation was repeated. 
The extracted plasmid DNA was transferred into a 15 ml polypropylene tube, 
and the EtBr removed from the DNA by adding equal volume of CsCI-saturated 
isopropanol. The solution was vortexed, centrifuged (1500g, 3 minutes, room 
temperature) and the upper pink isopropanol phase was removed and the 
process repeated until there were no traces of the pink EtBr. Finally, the lower 
aqueous phase containing plasmid DNA was transferred into a clean tube and 
diluted with 3 volumes of ddH2O followed by 2 volumes of 100% (v/v) ethanol 
and then incubated for 10 minutes at 4°C in order to precipitate the DNA. The 
DNA was collected by centrifugation (4,500g, 15 minutes, room temperature), 
washed with 70% (v/v) ethanol and re-centrifuged (4,500g, 15 minutes, room 
temperature). After centrifugation, the pellet was air-dried (20 minutes, room 
temperature) and re-suspended in 1 ml TE buffer (pH8.0). The maxi preparation 
was stored at -20°C until required. 
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2.8.3 RNA extraction 
Total RNA was prepared from cell pellets of the cell lines using the RNeasy total 
RNA kit (Qiagen, UK). Cells were lysed with 350 µl RLT lysis buffer containing 
3.5 µl ß-mercaptoethanol and then placed in a QIA shredder column and 
homogenised by centrifugation (13,000g, 1 minute, room temperature). 350 µl 
70% (v/v) ethanol was added to the homogenised lysate and placed in an 
RNeasy spin column and centrifuged (8,000g 15 seconds, room temperature). 
The flow-through was discarded and the spin column was washed with 700 µl 
RW1 buffer and re-centrifuged (8,000g, 15 seconds, room temperature). 
Following further washing with 500 µl RPE buffer, the spin column was 
centrifuged (13,000g, 2 minutes, room temperature) to ensure complete drying 
of the RNeasy spin column membrane. The RNA was eluted by the addition of 
35 µl RNase-free H2O to the column membrane, followed by incubation (30 
minutes, on ice) and centrifugation (8,000g, 1 minute, room temperature). The 
concentration of the RNA was calculated from its optical density at a 
wavelength of 260 nm using a UVmini 1240 spectrophotometer (Shimadzu, 
Japan). The eluted DNA can be stored at -20°C until needed. 
2.8.4 Reverse transcriptase - Polymerase Chain Reaction (RT-PCR) 
RT-PCR was performed using the TITANIUM One-Step RT-PCR Kit (Clontech: 
PT3397-2) to amplify the CETN2 gene from mRNA extracted from H413 cells. 
Primers that incorporated Xhol and Xmal restriction enzyme sites into the 5' and 
3' ends, respectively, were used. The primer sequences were: 
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Forward primer: 5'CTCGAGTGATGGCCTCCAACTTTAAGAAGGC3' 
(coding strand, nucleotides 48-67; an additional TG was added to the primer 
sequence in order to ensure that the CETN2 gene sequence was cloned `in 
frame') 
Reverse primer: 5'0006 ATAGAGGCTGGTCTTTTTCATGATGCGCAG3' 
(non-coding strand, nucleotides 534-563, which produced a 430 base pair 
fragment) 
RT-PCR was carried out using the following reaction mixture at final 
concentrations of 1X One-Step buffer, 1X dNTP mix, 20 units recombinant 
RNase Inhibitor, 25 µl thermostabilizing reagent, 10 µl GC-melt, 1 µl oligo(dT) 
primer, 1X RT-Titanium Taq enzyme mix, 1µg RNA sample, 0.5 µl of each 
forward and reverse primer (1µg/µl). The final volume was made up to 50 µl 
using RNase-free H2O. RT-PCR was carried out using a Gene Amp PCR 
System 2400 thermal cycler (Perkin-Elmer, UK). The initial synthesis of the 
cDNA strand was performed at 50°C for 1 hour. The mRNA-cDNA template was 
then denatured at 94°C for 5 minutes followed by 35 cycles of denaturation at 
94°C for 30 seconds, primer annealing at 65°C for 30 seconds, primer 
extension at 68°C for 1 minute and a final extension at 68°C for 7 minutes. The 
PCR products were visualised by agarose gel electrophoresis, as described 
(Section 2.8.6). The PCR product was cloned into the pCR4-TOPO vector, a 
commercially available kit for direct cloning of PCR products (TOPO TA Cloning 
Kit for Sequencing; Invitrogen), according to manufacturers instructions. A 
small-scale preparation of the pCR4-TOPO vector containing the PCR insert 
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was performed following transformation into competent E. coli cells, as 
described (Section 2.8.1), and stored at-20°C until required. 
2.8.5 Expression vector: pEGFP-C1 
The mammalian expression vector pEGFP-C1 (Clontech, UK) encodes a red- 
shifted variant of wild-type GFP (1-3), which has been optimised for brighter 
fluorescence and higher expression in mammalian cells. Genes cloned into the 
multiple cloning sites between the EGFP coding sequences and the SV40 poly 
A, will be expressed as fusions to the C-terminus of EGFP if they are in the 
same reading frame as EGFP. SV40 polyadenylation signals downstream of the 
EGFP gene direct proper processing of the 3' end of the EGFP mRNA. A 
neomycin resistance cassette (neo), consisting of the SV40 early promoter, the 
neomycin/kanamycin resistance gene, and polyadenylation signals from the 
Herpes simplex thymidine kinase (HSV TK) gene, allows stably transfected 
eukaryotic cells to be selected using G418. A bacterial promoter upstream of 
this cassette expresses kanamycin resistance in E. coll. The pEGFP-C1 
backbone also provides a pUC origin of replication for propagation in E. coil and 
an f1 origin for single-stranded DNA production. A map of pEGFP-C1 is shown 
in Figure 2.1. 
2.8.6 Restriction digestion and agarose gel electrophoresis 
Restriction enzyme digests were used to release the CETN2 cDNA from the 
pCR4-TOPO vector and to linearise the pEGFP-C1 vector for the purpose of 
sub-cloning the CETN2 gene into pEGFP-C1.1-5 µg plasmid DNA was 
digested with 5 units of Xhol, 5 units of Xmal, 3 µl 1 OX restriction enzyme buffer 
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D (Promega) and H2O added to a final volume of 30 µl. The plasmid was 
digested for 2 hours at 37°C and the reaction was terminated by the addition of 
3 µl of 1OX nucleic acid loading buffer (0.025% (w/v) bromophenol blue; 50% 
(v/v) glycerol; 1 mM EDTA; pH 8.0). The DNA fragments were separated on 1% 
(w/v) agarose gels containing 0.5X TBE buffer (0.089 M Tris-Borate (pH 8.3), 2 
mM EDTA) and 0.5 µg/ml EtBr (stock: 10 mg/ml). DNA markers of known 
molecular weight (Sigma: %DNA Hindill or (pX174 Haelll digest) were run in 
parallel. The DNA was visualised using a U. V. transilluminator with a 
wavelength of 254 nm. 
2.8.7 Purification of DNA from agarose gels 
The Sephaglas BandPrep Kit (Amersham Pharmacia Biotech, UK) was used to 
purify DNA from agarose gels. The DNA band of the correct molecular weight 
was excised from the agarose gel and placed in a 1.5 ml eppendorf. To a gel 
slice weighing less than 250 mg, 250 µl of gel solubiliser was added and the 
mixture incubated at 60°C for 10 minutes with intermittent vortexing until the 
agarose slice was dissolved. 5 gl Sephaglas BP suspension was added to the 
solution, incubated at room temperature and vortexed gently every minute for 5 
minutes. The Sephaglas pellet was collected by centrifugation (13,000g, I 
minute, room temperature) and the supernatant discarded. Centrifugation was 
repeated and any residual liquid was removed. The pellet was resuspended in 
80 gl wash buffer and collected by centrifugation (13,000g, 1 minute, room 
temperature). The wash step was repeated twice and supernatant discarded. 
The tube was tapped to disperse the Sephaglas pellet and air dried for 10 
minutes at room temperature. The pellet was re-suspended in 20 µl elution 
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buffer (1 mM EDTA; 10 mM Tris-HCI; pH 8.0) and incubated for 5 minutes at 
room temperature with periodic agitation. The solution was centrifuged 
(13,000g, 1 minute, room temperature) and the supernatant containing the 
purified DNA was used in ligation reactions in order to create plasmid 
constructs. 
2.8.8 Ligation 
A 2: 1 molar ratio of vector to insert was used for ligation. Ligation was carried 
out in solution containing, vector, insert, 1X ligation buffer, 100 U T4 DNA ligase 
(New England Biolabs, UK) and H2O added to the reaction mixture to make a 
final volume of 20 µI. Ligation was carried out overnight at 4°C and heat 
inactivated at 65°C for 10 minutes. 
2.8.9 Sequencing 
1µg of DNA was precipitated using 1/10-volume 3M sodium acetate and 2.5- 
volumes of ethanol at -20°C for 1 hour. The DNA was centrifuged (13,000g, 10 
minutes, 4°C) and the DNA pellet was washed with 70% ethanol. The pellet was 
air-dried and the sequencing reaction performed commercially by MWG 
(Germany). The sequence of the CETN2 gene is listed in Appendix II 
2.9 WESTERN BLOTTING 
2.9.1 Preparation of protein samples 
Cells were cultured until 70-80% confluent, harvested, counted (Section 2.4.4) 
and resuspended in sufficient PBS to yield 1x106 cell/ml. 1 ml aliquot of the cell 
suspension was transferred into sterile 1.5 ml eppendori tubes, centrifuged 
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(13,000g, 3 minutes, room temperature), the supernatant aspirated and the cell 
pellet stored at -70°C until needed. 
Prior to western blot analysis, the cell pellets were lysed in 50 pl of ice-cold 
RIPA buffer [0.15 M NaCl, 1% (v/v) Nonidet P40,0.5% (v/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 50 mM Tris-HCI (pH8.0)] containing 5pl 
protease inhibitor [cocktail set III (Calbiochem)], 1 mM sodium orthovanadate, 2 
mM sodium pyrophosphate, 5 mM p-glycerophosphate and 49.5 mM sodium 
fluoride. The lysates were vortexed and incubated on ice for 15 minutes and 
centrifuged (13,000g, 20 minutes, 4°C). The supernatant was collected and an 
equal volume of 2x gel sample buffer [100 mM Tris-HCI (pH6.8), 20% (v/v) 
glycerol, 200 mM dithiothreitol, 4% (w/v) bromophenol blue] was added. The 
samples were boiled for 5 minutes and used immediately or stored at -20°C 
until required. 
2.9.2 Polyacrylamide gel electrophoresis 
For resolution of proteins, the resolving gel consisted of 8% Protogel [30% (w/v) 
acrylamide, 0.8% (w/v) bisacrylamide)], 0.38 M Tris pH8.8,0.1% SDS, 0.1% 
ammonium persulphate (APS) and 0.06% N, N, N', N'-tetramethylethylenediamine 
(TEMED). The stacking gel consisted of 4.98% Protogel, 0.14 M Tris pH6.8, 
0.1% sodium dodecyl sulphate, 0.1% APS and 0.1% TEMED. The samples 
were electrophoresed in running buffer [0.38 M glycine, 49 mM Tris and 0.2 % 
SDS] (pH8.3), together with stained protein markers (Bio-Rad Precision Protein 
Standards), for 1'/2 hours at 30mAmp/gel. The separated proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon-P, pore 
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size; 0.45 pm, Millipore, UK). Prior to protein transfer, the PVDF membrane was 
soaked in methanol for 5 minutes and washed in Hoeffer buffer [0.19 M Glycine, 
0.02 M Tris, 0.04% SDS, 20% Methanol; (pH8.3). Proteins were transferred 
using a dry blotter, Semiphor Transfer Unit TE70 (Hoefer Scientific Instruments, 
USA) for 2 hours at 0.8 mAmp/cm2. 
Electroblotted membranes were blocked in milk block buffer [10 mM Tris-HCI 
pH8.0,150 mM NaCl, 4% non-fat dried milk, pH 7.4] for 1 hour to block non- 
specific binding of proteins. Membranes were incubated with primary antibodies 
in milk buffer, overnight on a rotator at 4°C. The membranes were then rinsed in 
ddH2O and washed twice in milk buffer, twice in Tween buffer [10 mM Tris/HCI, 
pH8,150 mM NaCl, 0.2% Tween-20 (w/v) (Sigma), pH 7.4] and finally in milk 
buffer, for 10 minutes each. The membranes were then incubated in horse- 
radish peroxidase (HRP)-conjugated secondary goat anti-mouse antibody 
(Sigma), at 1: 1000 dilution, in milk buffer for 1 hour on a rotator at room 
temperature. The membranes were then washed for 20 minutes in milk buffer 
on a rocking platform at room temperature, followed by a 10 minute wash in 
Tween buffer and then rinsed in ddH2O. The peroxidase activity was detected 
using an Enhanced Chemiluminescence (ECL) detection kit (Amersham), 
following the manufacturer's instructions and developed on Kodak X Omat film. 
Equal loading of proteins was confirmed by incubating the blot in the primary 
antibody alpha-tubulin (Sigma) at dilution 1: 10,000 in milk block buffer and 
detected as described above. 
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For the detection human MLH1 and MSH2 proteins, primary mouse monoclonal 
anti-human MLH1 and MSH2 (BD Pharmingen) antibodies were used at a 
dilution of 1: 250. 
For detection of p21 and MDM2 proteins, primary mouse monoclonal anti- 
p21Waf' (Oncogene: OP64) and MDM2 (Oncogene: OP46T) antibodies were 
used at 1: 100 dilutions. Primary mouse monoclonal anti-p53 antibody was 
provided by Dr. Chris Paraskeva and was used at a dilution of 1: 100. 
2.10 TREATMENT OF CELLS WITH THE CHEMICAL CARCINOGEN PHIP 
OKF6/TERT-1 cells were grown to 50% confluence and harvested as described 
previously. 1x106 cells were incubated in suspension with 50 µM PhIP [stock: 
50 mM in DMSO (ICN)], 0.4 mg/ml Aroclor 1254-induced S9 rat liver extracts 
(Moltox Boone, NC), 0.23 mM NADP, 0.28 mM glucose 6-phosphate, 0.45 mM 
MgCl2,0.45 mM KCI and 200 mM Tris. HCI (pH7.5) in KSFM medium at 37°C, 
for 3 hours with intermittent shaking. Controls included cells treated with an 
equal volume of DMSO. Following PhIP treatment, cells were centrifuged (60g, 
10 minutes, room temperature), washed in serum free epithelial medium and re- 
seeded in KSFM medium. The PhIP treated cells were allowed to recover 
exponential growth, harvested and re-treated as above and seeded in 90 mm 
dishes. Cells were allowed to grow until they formed colonies of approximately 
1000 cells and single cell clones were obtained using cloning rings as described 
previously (Section 2.4.9). 
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To identify PhIP resistant clones, 1x106 cells of PhIP clones were treated with 
50 µM of PhIP, as described above and seeded in 25cm2 flasks and allowed to 
grow for 14 days until colonies were visible. 1x106 parental OKF6/TERT-1 cells 
were treated in parallel as controls. Cells were then washed with PBS (pH7.2) 
and fixed in 10% formol saline (36g NaCl in 10% formaldehyde) for 10 minutes 
and stained with 0.5% methylene blue/PBS (pH7.2) solution. The relative 
resistance of PhIP clones was normalised to the plating efficiency of untreated 
controls. Clones that formed more or bigger colonies in comparison to PhIP 
treated parental cells were, therefore, considered PhIP resistant. 
2.11 COMPARATIVE GENOMIC HYBRIDISATION (CGH) 
The Qiagen Blood and Cell Culture DNA Kit (Cat. no. 13323) was used to 
extract genomic DNA from cell lines. Cells were harvested through trysinization 
as described (Section 2.4.4) and genomic DNA was extracted according to the 
manufacturers instructions. Briefly, cells were resuspended in PBS to a final 
concentration of 107 cells/ml and 0.5 ml (5x10) was used per reaction. The cell 
suspension was transferred to a 15 ml falcon tube and lx volume of ice-cold 
buffer C1 and 3x volume ice-cold ddH2O were added. The solution was mixed 
by inverting the tube, incubated on ice for 10 minutes and centrifuged (4000g, 
15 minutes, 4C). The supernatant was discarded and the process repeated. 
Following centrifugation, the pellet was resuspended in 1 ml buffer G2 and 
treated with 25 µl proteinase K solution at 50°C for 60 minutes. Before 
harvesting the genomic DNA, the QIAGEN tip with was equilibrated with 2 ml 
buffer QBT and the proteinase K treated sample was applied to the equilibrated 
tip. The tip was washed 3x with 1 ml of buffer QC and the genomic DNA eluted 
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2x with 1 ml buffer QF, prewarmed to 50°C. 0.7x volume of room temperature 
isopropanol was added and the precipitated DNA harvested by centrifugation 
(4,500g for 15 minutes, 4°C). The DNA pellet was washed with 1 ml of cold 70% 
ethanol and centrifuged (4,500g for 15 minutes, 4°C). The DNA pellet was air 
dried for 5-10 minutes at room temperature, resuspended in 0.1 ml TE (pH8) 
and left at room temperature to dissolve and stored at -20°C. 
CGH was carried out in collaboration with Dr. P. Murray (Division of Cancer 
Studies, University of Birmingham) using a previously described method (Dyer 
et al., 2002). Briefly, tumour and reference DNA were nick-translated and 
directly labelled with Spectrum Green-2'-deoxyuridine-5'-triphosphate and 
Spectrum Red-2'-deoxyuridine-5'-triphosphate (Vysis, Downers Grove, IL), 
respectively. The volume of enzyme mix and incubation period were varied to 
give fragment sizes of 200 to 5000 bp as determined by gel electrophoresis. 800 
ng of tumor DNA, 400 ng of reference DNA, and 30 pg of Cot-1 DNA 
(Invitrogen, UK) were co-precipitated and resuspended in 3 pi of nuclease-free 
H2O and 7 pl of CGH hybridization buffer (Vysis). The probe mixture was 
denatured (75°C, 5 minutes) and hybridized to denatured, dehydrated male 
metaphase slides (Vysis) at 37°C for 72 hours. Slides were washed in 0.4x 
standard saline citrate/0.3% Nonidet P-40 (75°C, 2 minutes) and 2x standard 
saline citrate/0.1 % Nonidet P-40 (room temperature, 30 seconds) and 
counterstained with 4,6-diamino-2-phenylindole (125 ng/ml) in anti-fade solution. 
Red, green, and blue images from representative metaphase spreads were 
digitized using a Cytovision (Applied Imaging, Santa Clara, CA) imaging system. 
Karyotypes from 15 metaphases were combined to produce a mean CGH ratio 
profile for each hybridization. Detection of imbalances was performed using 
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Applied Imaging CytoVision High-Resolution CGH (HRCGH) software, which 
allows direct comparison of a mean CGH profile from a test hybridization with 
standard reference intervals produced from a series of CGHs using normal test 
DNA. Regions where the mean CGH ratio profile, confidence limits, and 
standard reference intervals deviate from each other represent areas of 
genomic imbalance in the test specimen. A test: reference fluorescence ratio 
>1.5 was classified as a high-level gain, whilst a ratio of < 0.5 was classified as 
a loss. 
2.12 DNA PLOIDY ANALYSIS OF ARCHIVAL ORAL TISSUES 
Ploidy analysis of oral archival material was carried out in collaboration with Dr. 
J. Sudbo (Norwegian Radium Hospital, University of Oslo, Norway) using a 
previously described method (Sudbo et al., 2001a). Two 50 pm sections of 
paraffin-embedded blocks of biopsy specimens were deparaffinized, rehydrated 
and enzymatically digested (type XXIV protease, Sigma) to yield a suspension 
of nuclei. The suspension was centrifuged, and the pellet was resuspended and 
placed on a slide to form a monolayer. The monolayer was the stained with 
Feulgen's and periodic acid-Schiff stain in order to assess the DNA content of 
the nuclear DNA 
The DNA content of nuclei stained with Feulgen's stain and periodic acid-Schiff 
stain was measured and analyzed using the Fairfield ploidy system (Fairfield 
Imaging, Kent, United Kingdom). The nuclei of at least 300 cells were 
measured, and the information was stored in a computerized folder, or "gallery, " 
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Figure 2.1 Mammalian expression vector pEGFP-C1 
The CETN2 gene was inserted between the Xhol and Xmal site within the 
multiple cloning site of the plasmid. 
t3: 'iG t. G t36G 73; G 737G flý 13, J 1ý gTýiPý 
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CHAPTER THREE 
THE ANALYSIS OF THE MITOTIC AND TETRAPLOIDY 
CHECKPOINTS IN HUMAN OSCC-DERIVED CELL LINES 
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3.1 INTRODUCTION 
CIN and MIN are two mutually exclusive types of genetic instability, such that a 
tumour would have one abnormality or the other, but rarely both together 
(Lengaur et al., 1997; 1998). CIN is characterised by an abnormal number of 
chromosomes, termed aneuploidy (Rajagopalan et a/., 2004), whilst MIN is 
characterised by a widespread alteration of microsatellite sequences (Yamasaki 
and Mironov, 2000) due to mutations in mismatch repair (MMR) genes 
(Buermeyer et al., 1999). At least five human genes (hMSH2, hMSH6, hMLH1, 
hPMS1 and hPMS2) are known to participate in the MMR pathway but 
mutations in the hMLH1 and hMSH2 genes have been shown to account for the 
majority of mismatch repair defects (Jiricny and Lahti, 2000). 
Previous work has showed that the H-series of OSCC-derived cell lines (H103, 
H157, H314, H357, H376, H400, H413; Prime et al., 1990) exhibited alterations 
in chromosome numbers (Patel et al., 1993), indicating that these cells were 
aneuploid and exhibit CIN. Therefore, these cell lines represent a unique model 
to determine whether defects in the chromosome segregation machinery could 
be the underlying cause of CIN in oral cancer. The MIN status of these cell 
lines, however, is not known. 
Accumulating evidence suggests that defects in the chromosome segregation 
machinery such as the mitotic (Saeki et al., 2002, Ouyang et al., 2002, Wang et 
al., 2002) and tetraploidy checkpoints (Andreassen et al., 2001 a) could play an 
important role in the development of aneuploidy and CIN. The mitotic 
checkpoint ensures the fidelity of chromosome segregation during cell division, 
whilst the tetraploidy checkpoint functions downstream of the mitotic checkpoint 
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and acts by recognising and inducing a cell cycle arrest in cells exiting mitosis 
with a tetraploid DNA content. There is a paucity of information, however, 
regarding the integrity of these checkpoints in oral cancer. 
The aim of the present study, therefore, was to confirm that the H-series of the 
OSCC-derived cell lines express the hMLH1 and hMSH2 proteins and then to 
examine the fidelity of the mitotic checkpoint in the same series of cell lines. 
The study was extended to analyse the integrity of the tetraploidy checkpoint in 
those cell lines that exhibited an aberrant G2/M arrest during prolonged 
nocodazole treatment. 
3.2 RESULTS 
3.2.1 Basal expression of hMLHI and hMSH2 proteins in human OSCC- 
derived cell lines 
To analyse the status of the MMR pathway, the basal expression of the hMLH1 
and hMSH2 proteins was analysed in the H-series of OSCC-derived cell lines. 
Western blot analysis showed that all cell lines expressed both hMLHI and 
hMSH2 (Figure 3.1). HCT116, a colorectal cancer cell line, was used as a 
control because it fails to express the hMLH1 protein, rendering it MMR 
deficient (Bardelli et al., 2001). 
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3.2.2 Analysis of the mitotic checkpoint 
3.2.2.1 Cell cycle analysis 
To determine the status of the mitotic checkpoint in the OSCC-derived cell lines, 
the response of the cell lines following activation of the mitotic checkpoint was 
assessed by FACS. A human colorectal cancer cell line, HCT116, shown 
previously to have an intact mitotic checkpoint (Tighe et al., 2001) was used as 
a control. 
The mitotic checkpoint was activated by treating the cells with 0.2 µg/ml 
nocodazole. FACS analysis performed after 18 hours of nocodazole treatment 
examined the ability of the cells to arrest at G2/M and analysis after 36 hours of 
treatment showed whether the cells were able to maintain the G2/M arrest or if 
they proceeded to reduplicate their DNA following prolonged perturbation of the 
microtubule network 
The FACS profile of diluent (DMSO) treated asynchronous control HCT116 cells 
exhibiting GO/G1 (diploid; 2N) and G2/M (tetraploid; 4N) peaks is shown in 
Figure 3.2A; a similar profile was observed in diluent treated cultures of all the 
other cell lines (data not shown). Treatment of the OSCC-derived cell lines and 
HCT116 with nocodazole for 18 hours resulted in the majority of cells (62%- 
100%) arresting at G2/M, indicating an intact mitotic checkpoint (Figure 3.2B, 
Figure 3.3). An additional GO/G1 arrest was also seen in H157 (24.5%) and 
H413 (6.3%). 
Following 36 hours of nocodazole treatment, the majority of cells (48%-85%) in 
the H103, H157, H314, H400, H413 and HCT116 cell lines were arrested at 
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G2/M with a tetraploid DNA content (Figure 3.2C, Figure 3.4). H157 also 
continued to maintain a high proportion of cells at GO/G1 (25%) after 36 hours 
of treatment (data not shown). By contrast, H357 and H376 exhibited only a low 
percentage (19%-34%) of cells arrested at G2/M. 
Whilst only a small subpopulation (1.4%-7%) of H103, H157, H314, H400, H413 
and HCT116 cells went on to reduplicate their DNA in the presence of 
nocodazole (Figure 3.2C, Figure 3.4), a substantial number of H357 and H376 
cells (20% and 63%, respectively) showed evidence of DNA reduplication 
(Figure 3.4). The cell cycle analysis of H376 cells treated for 36 hours with 
nocodazole is shown in Figure 3.5. 
3.2.2.2 Mitotic indices 
To confirm the status of the mitotic checkpoint in the OSCC-derived cell lines, 
the mitotic index (percentage of cells in mitosis) of cells treated with nocodazole 
for 12-42 hours was determined by immunofluorescence analysis using an anti- 
phospho-histone H3 antibody. The majority of the diluent treated asynchronous 
control HCT116 cells lacked phospho-histone H3 staining (Figure 3.6A), whilst 
the majority of nocodazole treated cells had condensed chromatin positive for 
phospho-histone H3, indicating cells in mitosis (Figure 3.6B). Similar staining 
patterns for phospho-histone H3 were seen in all the OSCC-derived cell lines 
before and after treatment with nocodazole (data not shown). 
With the exception of H376, the greatest number of mitotic cells was observed 
between 18-24 hours in all cell lines following nocodazole treatment (Figure 
3.7). The number of mitotic cells fell to basal levels after 36-42 hours. The drop 
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in the percentage of cells in mitosis after 24 hours indicates the exit of the 
mitotic cells to GO/G1. H376 exhibited a similar trend, albeit at a faster rate. 
The increase in the percentage of mitotic cells observed between 18-24 hours 
of nocodazole treatment suggests a transient mitotic arrest, indicating a 
functional mitotic checkpoint. H357 and H400 cells behaved in a similar way to 
HCT116 controls with approximately 70% of cells in mitosis after 18 hours 
treatment with nocodazole, indicating an intact mitotic checkpoint. By contrast, 
only 37%-55% of H103, H157, H314 and H413 cells and 51.4% of H376 cells 
were in mitosis after 18 and 12 hours of incubation, respectively, suggesting 
that the mitotic checkpoint might be compromised in these cell lines. 
3.2.3 Tetraploidy checkpoint analysis 
The high level of DNA reduplication observed in H357 and H376 following 36 
hours of nocodazole treatment suggests a defective post-mitotic or tetraploidy 
checkpoint. To test this hypothesis, the ability of H357 and H376 cells to arrest 
with a tetraploid DNA content following transient exposure to 
dihydrocytochalasin B (DCB), an agent known to inhibit cytokinesis, was 
analysed by FACS. H400, which exhibited a minimal amount of reduplication, 
was used as a control. 
Asynchronous cultures of H400 exhibited a cell cycle profile corresponding to 
the GO/G1, S and G2/M phases of the cell cycle (Figure 3.8A). The cells were 
first pre-synchronized with 0.04 µg/ml nocodazole for 18 hours prior to 
treatment with DCB. Nocodazole treated cells accumulated at the G2/M phase 
with a 4N DNA content and were able to exit the arrest and begin cycling within 
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5 hours of release into drug free medium (Figure 3.8B). The nocodazole pre- 
synchronised cells were harvested through `mitotic shakeoff and replated in 10 
µM DCB for 5 hours. A G2/M arrest was seen following DCB treatment of 
nocodazole pre-synchronised cells, which taken together with the observation 
that the nocodazole pre-synchronised cells began cycling following release into 
drug free medium, shows that the DCB treatment is responsible for the arrest 
(Figure 3.8C). After 5 hours exposure to DCB, the cells were then released into 
drug free medium and harvested after 18 hours for FACS analysis. H400 was 
able to maintain the arrest induced by DCB after 18 hours of release into drug 
free medium (Figure 3.81D). 
By contrast, although H357 and H376 exhibited a G2/M arrest following 
treatment with DCB, within 18 hours of release into drug free medium, H357 
cells exhibited a tendency towards emergence of a polyploidy cell population as 
seen through the progression of cells arrested at G2/M into S-phase (Figure 
3.9A) whilst H376 already exhibited an 8N population resulting from DNA 
reduplication (Figure 3.9B). However, a polyploid population of cells was 
observed in H357, H376 and H400,36 hours after release into drug free 
medium (data not shown). 
3.3 SUMMARY 
This study initially examined the expression of the hMLH1 and hMSH2 proteins 
in the H-series of OSCC-derived cell lines in order to determine the status of the 
MMR pathway and to exclude the presence of MIN in these cell lines. All of the 
cell lines expressed both hMLH1 and hMSH2 proteins indicating that they have 
an intact MMR pathway and, therefore, are likely to be microsatellite stable. 
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Taken together with the previously reported chromosome number alterations in 
the H-series (Patel et al., 1993), the results show that the cell lines used in the 
present study exhibit CIN and not MIN. 
The study was then extended to examine the status of the mitotic checkpoint in 
the same series of cell lines. A G2/M arrest was observed in all cell lines 
following 18 hours of nocodazole treatment, as assessed by FAGS, indicating 
an intact mitotic checkpoint. Examination of the mitotic indices after 18 hours of 
nocodazole treatment showed that H357 and H400 behaved in a similar way to 
control HCT116 cells with approximately 70% of cells in mitosis, whilst a lower 
percentage of cells in mitosis (37%-55%) was seen in the remaining cell lines. 
Taken together, the results indicate that the mitotic checkpoint is intact in all the 
cell lines but it is possible that the function of the checkpoint is attenuated in five 
of seven cell lines. 
Examination of the cell cycle after 18 hours release from DCB treatment 
revealed a G2/M arrest in H400 cells indicating that the tetraploidy checkpoint 
was intact. By contrast, the S-phase progression observed in H357 and the 
emergence of a polyploid cell population in H376 suggests that the tetraploidy 
checkpoint was defective in these cell lines. However, the fact that polyploid cell 
populations emerged in all cell lines after 36 hours release from DCB treatment 
suggests that the checkpoint could be defective in all cell lines. This may be due 
to the mutations in the p53 gene harboured by these cells and it has been 
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Figure 3.1 Western blot analysis of the expression of hMLH1 and hMSH2 
proteins 
Expression of both hMLH1 and hMSH2 proteins in all cell lines of the H-series 
indicates an intact MMR pathway. Proteins were detected using anti-hMLH1 
and anti-hMSH2 antibodies. The additional bands on the hMLH1 blot are non- 
specific and were normally present during the analyses. HCT1 16, which fails to 








Figure 3.2 Cell cycle analysis of HCT116 cells indicating an intact 
mitotic checkpoint 
(A) Diluent (DMSO) treated control HCT116 cells exhibited GO/G1, G2 and S 
phase peaks, indicating an asynchronous replicating population of cells. (B) 
Cells treated in 0.2 µg/ml nocodazole for 18 hours arrested at the mitotic phase 
with a large G2/M peak, indicating an intact mitotic checkpoint. (C) G2/M phase 
arrest was maintained after 36 hours in nocodazole with a small population of 
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Figure 3.3 Cell cycle analysis of the H-series of OSCC-derived cell lines 
exhibiting GO/G1 and G2/M arrest following 18 hours incubation in 0.2 
µg/ml nocodazole. 
HCT116, known to have an intact mitotic checkpoint was used as a positive 
control. All cell lines of the H-series, and the HCT116 control cells exhibited a 
high percentage of G2/M arrest, indicating an intact mitotic checkpoint. Data 
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Figure 3.4 Cell cycle analysis of the H-series of OSCC-derived cell lines 
exhibiting G2/M arrest and DNA reduplication following 36 hours 
incubation in 0.2 µg/mI nocodazole. 
All OSCC-derived cell lines and HCT1 16 exhibited a G2/M arrest and showed 
evidence of DNA reduplication in a varying proportion of cells. H357 and H376 
exhibited DNA reduplication in a high percentage of cells relative to the other 
cell lines, indicating an inability to maintain arrest following prolonged 
nocodazole treatment. Data points reflect the means (± standard deviation) of 
two separate experiments. 
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Figure 3.5 Cell cycle analysis of H376 cells exhibiting DNA reduplication 
following 36 hours incubation in 0.2 µg/ml nocodazole 
(A) Diluent (DMSO) treated control cells exhibited GO/G1, G2 and S phase 
peaks, indicating an asynchronous replicating population of cells. (B) Following 
18 hours of nocodazole treatment, the majority of cells arrested at G2/M, 
indicating an intact mitotic checkpoint. (C)The majority of the 4N cells have 
reduplicated their DNA, resulting in an 8N peak after 36 hours in nocodazole, 
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Figure 3.6 Immunofluorescence image of anti-phospho histone H3 
stained HCT116 cells. 
Cells were stained with anti-phospho histone H3 primary and FITC conjugated 
secondary antibodies, which detected cells with condensed chromatin (green) 
characteristic of cells in the mitotic phase. The nuclei were counterstained with 
DAPI (blue). An increase in the number of mitotic cells with condensed 
chromatin was observed in (B) nocodazole treated cells compared to (A) diluent 
treated control cells. 
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Figure 3.7 Mitotic index of the H-series of OSCC-derived cell lines 
during incubation in 0.2 µg/ml nocodazole. 
Similar to HCT116, H357 and H400 exhibited a peak in the percentage of 
mitotic cells between 18-24 hours of incubation in 0.2 µg/ml nocodazole, 
demonstrating a transient cell cycle arrest following microtubule perturbation. A 
similar peak with lower percentage of cells in H103, H157, H314, H376 and 
H413 suggests a compromised mitotic checkpoint in these cell lines. H376 
exhibited a similar trend, at a faster rate. The decline in the percentage of 
















Figure 3.8 Cell cycle analysis of H400 cells following pre- 
synchronization with nocodazole and DCB treatment 
(A) Asynchronous H400 cells exhibited 2N, 4N and S-phase peaks. (B) 
Nocodazole pre-synchronised cells were able to exit G2/M arrest within 5 hours 
of release into drug free medium. (C) Transient 5 hours incubation of 
nocodazole pre-synchronised cells in 10 µM DCB induced a G2/M arrest. (D) 













Figure 3.9 Cell cycle analysis of H357 and H376 cells after 18 hours 
following release from DCB. 
(A) H357 cells arrested at G2/M showed evidence of progression into S-phase, 
exhibiting a trend towards emergence of a polyploid population of cells (B) 8N 
cells emerged in the H376 cell line within 18 hours of release from DCB into 
drug free medium. 
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CHAPTER FOUR 
THE ANALYSIS OF CENTROSOME ABNORMALITIES IN HUMAN 
OSCC-DERIVED CELL LINES 
82 
4.1 INTRODUCTION 
The result of Chapter 3 demonstrated that the H-series of human OSCC- 
derived cell lines expressed hMLH1 and hMSH2, which confirmed earlier 
cytogenetic data to indicate that the cells exhibited CIN. Analysis of the mitotic 
checkpoint revealed that this checkpoint was functional in all cell lines although 
its function may be attenuated in five of seven cell lines. A compromised mitotic 
checkpoint could allow low levels of chromosome missegregation, but is unlikely 
to be responsible for the marked cytogenetic abnormalities seen in these cell 
lines (Patel et al., 1993). It is likely, therefore, that alternative mechanisms are 
responsible for the CIN in these cell lines. 
The centrosome is a part of the chromosome segregation machinery which 
functions to nucleate and organise the mitotic spindle for equal segregation of 
chromosomes during mitosis. Centrosome abnormalities have been reported in 
cell lines derived from pancreatic (Sato et al., 2001), colon (Ghadimi et al., 
2000) and breast cancers (D'Assoro et al., 2002). The common centrosome 
abnormalities observed in these cells include supernumerary centrioles, 
centrosome of larger diameter, mislocalised centrosomes and compromised 
function. These abnormalities are suggested to predispose cells to multipolar 
mitosis, resulting in erroneous chromosome segregation and CIN (Sato et a/., 
2001) and interestingly, centrosomal abnormalities have been observed 
exclusively in aneuploid cell lines but not in chromosomally stable MIN lines 
(Ghadimi et al., 2000). There is a paucity of information, however, on the 
occurrence of centrosomal abnormalities in oral cancer. 
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The purpose of the present study was to i) determine if defects of the 
centrosome, in terms of number, size and localization, occurred in the H-series 
of OSCC-derived cell lines and ii) to evaluate centrosome function in these cell 
lines by examining the capacity of the centrosomes to nucleate microtubules 
following microtubule depolymerization. The study was then extended to 
examine the stability of centrosomes in a cloned population of H413 cells 
because parental H413 cells exhibited a high level of centrosome abnormalities. 
4.2 RESULTS 
4.2.1 Centrosome identification and evaluation criteria 
Centrosomes were visualised through co-localization of immunofluorescence 
staining of two different antibodies directed against intrinsic components of the 
centrosome, namely y-tubulin and pericentrin. Both pericentrin and y-tubulin are 
located within the pericentriolar material (PCM) surrounding the centrosome; in 
normal human oral keratinocytes, centrosomes appeared as one or two 
punctate structures adjacent to the nucleus (Figure 4.1). 
When analysing the cell lines, cells exhibiting one or two centrosomes were 
considered to be normal, whilst cells exhibiting more than two centrosomes 
were considered to have centrosome hyperamplification. The presence of 
abnormalities in centrosome morphology and localization were qualitatively 
determined through comparison between centrosomes of normal human oral 
keratinocytes and the tumour cells or with populations of cells within the tumour 
cell lines exhibiting normal centrosome morphology and number. 
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4.2.2 Analysis of centrosome abnormalities in human OSCC-derived cell 
lines 
The percentage of cells exhibiting more than two centrosomes in the human 
OSCC-derived cell lines, human normal oral keratinocytes and the control MIN 
(HCT116) and CIN (CaCo2) cell lines is shown in Table 4.1. 
Centrosome analysis of the chromosomally stable control cell line, HCT116 
(MIN and near diploid), revealed a pattern indistinguishable from normal human 
oral keratinocytes. By contrast, CaCo2, the aneuploid control CIN cell line, 
exhibited centrosome hyperamplification in a high percentage of cells (23.81%). 
Similarly, five of the seven OSCC-derived CIN lines (H103, H157, H314, H400 
and H413) exhibited alterations in centrosome number, with H103 and H413 
showing the highest levels of centrosome hyperamplification (12.5% and 18.8%, 
respectively. 3-14 centrosomes per nuclei were observed in a subpopulation of 
cells in each cell line and up to 22 centrosomes per nuclei were observed in a 
subpopulation of H103 cells (Figure 4.2A, B). Some of the supernumerary 
centrosomes were detached from the nucleus and many of the supernumerary 
centrosomes were heterogeneous in size (Figure 4.2C). Further, dispersed 
pericentrin staining that did not co-localise with y-tubulin was observed in some 
cells with centrosome hyperamplification (data not shown). Multipolar mitoses 
were frequently observed in H103 and H413, cell lines with a high degree of 
centrosome hyperamplification. Although infrequent, multiple centrosomes were 
seen to cluster at the spindle poles in an attempt to create a bipolar spindle 
(data not shown). The centrosome profile of the remaining OSCC-derived cell 
lines, H357 and H376, was similar to that of normal human oral keratinocytes. 
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4.2.3 Analysis of centrosome function in human OSCC-derlved cell lines 
To examine centrosome function in the cell lines, the microtubule nucleation 
capacity of the centrosomes was evaluated in terms of their ability to nucleate 
microtubules from the endogenous pool of cytoplasmic a and ß tubulin, 
following nocodazole induced microtubule depolymerization. Microtubule 
nucleation was observed as aster formation at the nuclear periphery after 
release from nocodazole. The nucleation capacity of the centrosomes in the H- 
series of OSCC-derived and the control cell lines is shown in Table 4.1. 
The nucleation capacity of the control cell lines HCT116 and CaCo2 was 
similar, as demonstrated by aster formation in the majority of their cells (95.28% 
and 76.36%, respectively) by 2 minutes after release from nocodazole (Figure 
4.3, Table 4.1). A varied response was observed amongst the OSCC-derived 
CIN lines, with 18.45% - 82.35% of cells nucleating microtubules. 
No clear association was observed between the centrosome hyperamplification 
status and the ability of the centrosomes to nucleate microtubules after 2 
minutes release from nocodazole. For example, H413 and H376 exhibiting high 
(18.8 %) and low (0.4%) centrosome hyperamplification showed aster formation 
in the majority of cells (82.35% and 75.23%, respectively), whilst the remaining 
cell lines exhibited asters formation in only 18.45%-60.4% cells by 2 minutes 
following release from nocodazole (Figure 4.4A-C). Excessive microtubule 
nucleation in H413 cells (Figure 4.4D) and unorganised microtubule network 
formation in H357 cells were observed following 2 minutes release from 
nocodazole. 
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Dual staining of the microtubule-organizing centres with antibodies against a- 
tubulin and pericentrin showed that microtubule nucleation was invariably 
initiated from one or two centrosomes, suggesting that not all of the numerous 
centrosomes in cells with centrosomal hyperamplification are functional (data 
not shown). All cell lines fully recovered their tubulin network after 30 minutes 
release from nocodazole (Figure 4.3C, Figure 4.4C). 
4.2.4 Analysis of centrosome stability in the H413 OSCC-derived cell 
line exhibiting high centrosome abnormalities. 
To examine the stability of centrosome abnormalities, the ability of a cloned 
population of cells from a cell line exhibiting centrosome hyperamplification, to 
maintain a stable centrosome number was investigated. The H413 cell line 
exhibiting the highest percentage of centrosomal hyperamplification was 
selected. Briefly, the centrosome was labelled with EGFP following transfection 
of cells with human centrin-2 (CETN2) cDNA, cloned in-frame into the C- 
terminal enhanced green fluorescent protein vector (EGFP). Stable clones were 
obtained and the localization of CETN2 to the centrosome was confirmed by co- 
localization of y-tubulin staining through immunofluorescence, as both CETN2 
and y-tubulin are intrinsic components of the centrosome (Figure 4.5). A total of 
three H413 clones expressing CETN2-EGFP and three untransfected H413 
clones were analysed. Centrosomes in the untransfected clones were 
visualised by staining with antibodies against y-tubulin and pericentrin (data not 
shown). Centrosomes were designated as stable if the expanded culture of the 
cloned population of cells maintained normal centrosome number and unstable 
if a mixture of cells with normal and multiple centrosomes were seen. 
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The majority of cells in both CETN2-EGFP tagged and untransfected H413 
clones maintained normal centrosome number. However, a small sub- 
population of cells in all six clones, exhibited abnormalities in centrosome 
numbers and size. This suggests that centrosome duplication might have been 
uncoupled from the cell cycle in the H413 cells, thus giving rise to progenies 
with numerous centrosomes. A CETN2-EGFP tagged clone exhibiting the 
normal two (Figure 4.5A) and multiple centrioles (Figure 4.5B) is shown in 
Figure 4.5. 
4.3 SUMMARY 
This study examined centrosomal abnormalities in human OSCC-derived cell 
lines. By contrast to the control diploid and chromosomally stable MIN HCT116 
cell line, centrosome number abnormalities were observed in five of seven 
OSCC-derived cell lines. Alterations in centrosome size, localization and 
overexpression of pericentriolar matrix protein were also detected. The 
prevalence of centrosome abnormalities in the cell lines suggests that it may be 
a widespread phenomenon in oral cancer. 
Analysis of the capacity of cells to nucleate microtubules revealed that despite 
an initial delay in microtubule nucleation, the full recovery of the tubulin network 
after 30 minutes of release from nocodazole suggests that the centrosomes in 
all the OSCC-derived cell lines are fully functional. However, a possible 
impairment of other aspects of the centrosome was suggested by the excessive 
and unorganised microtubule nucleation observed in H413 and H357. 
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The analysis of cloned population of H413 cells transfected with CETN-EGFP 
showed that they are unable to maintain a stable centrosome number because 
a subpopulation of cells exhibited numerous centrosomes. This suggests that 
the morphologically normal centrosomes within cell lines exhibiting centrosome 
abnormalities might have an intrinsic centrosome instability that could result in 
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A subpopulation of H103 cells exhibiting normal numbers of centrosomes 







Numerical and morphological centrosomal aberrations in H103 
Figure 4.2 Types of centrosome abnormalities observed in the 
aneuploid H103 cell line. 
The cells of the H103 cell line exhibited various degree of centrosomal 
abnormalities. (A) A subpopulation of cells maintained normal centrosome 
numbers (x400), (B) while some cells exhibited up to 12 centrosomes per nuclei 
(x2000). (C) The excess centrosomes also exhibited heterogeneity in size. 
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Table 4.1 Degree of hyperamplification and microtubule nucleation 
function of the centrosomes in human OSCC-derlved and control cell 
lines 
Cell line Hyperamplification Nucleation 
Normal keratinocytes 1.9 ND 
HCT116 1.4 95.28 
CaCo2 23.81 76.36 
H103 12.5 51.96 
H157 6.9 18.45 
H314 3.2 60.40 
H357 0 37.50 
H376 0.4 75.23 
H400 5.5 25.38 
H413 18.8 82.35 
1Hyperamplification is expressed as the percentage of cells with more than 2 
centrosomes per cell in a minimum of 200 cells counted. 
2 Nucleation is expressed as percentage of cells capable of nucleating 
microtubule after 2 minutes release from 10 µg/ml nocodazole. A minimum of 
200 cells was scored. 
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Figure 4.5 Immunofluorescence co-localization of CETN2-EGFP signals 
with antibody against y-tubulin of the centrosome to authenticate CETN2 
targeting to the centrosome in a clonal population of transfected H413 
cells. 
The centrosomes were observed as green fluorescent dots due to localization 
of the EGFP tagged CETN2 protein to the centrosome, whilst the staining of the 
centrosome by the primary y-tubulin antibody was detected using secondary 
Cyc 3 antibody (red). The CETN2-EGFP transfected H413 clones exhibited (A) 
a population of cells showing normal number of centrosomes, with centrioles at 
close proximity to each other, near the nucleus and (B) a mixed population of 




CENTROSOME ABNORMALITIES AND DNA PLOIDY IN ORAL 
PREMALIGNANT LESIONS AND CARCINOMAS 
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5.1 INTRODUCTION 
Recent studies have demonstrated the importance of aneuploidy as a marker of 
malignant progression and patient prognosis in oral cancer. DNA ploidy analysis 
in non-dysplastic oral lesions demonstrated that aneuploidy can occur very 
early in oral cancer (Sudbo et al., 2001b) and that aneuploid lesions have a 
higher and faster rate of malignant progression in contrast to diploid and 
tetraploid lesions (Sudbo et al., 2001a). Furthermore, the presence of 
aneuploidy associated strongly with poor survival (Sudbo et al., 2004). 
The presence of centrosome abnormalities is a feature common to many 
human tumours (Pihan et al., 1998). Centrosomal defects appear early in 
cancer (Pihan et al., 2003) and are frequently associated with loss of tissue 
architecture (Pihan at al., 2001) and tumour aggressiveness (D'Assoro et al., 
2002). Centrosome abnormalities have been suggested to drive CIN and, in 
turn, cancer by their ability to cause chromosome missegregation through 
abnormal mitosis. (Shono et al., 2001). Consistently, coexistence of centrosome 
defects with aneuploidy has been reported in pre-invasive lesions (Pihan et a/., 
2003) and carcinomas of a variety of cancers (Gustafson et al., 2000, Sato et 
a/., 2001, Jiang et al., 2003), suggesting that centrosome defects may 
contribute to the earliest stages of cancer development through the generation 
of chromosome instability. 
There is currently a lack of information about the centrosomes status in oral 
cancer and the contribution of such abnormalities to oral tumour progression is 
unknown. The results of Chapter Four demonstrated that centrosome 
abnormalities are common in OSCC-derived CIN cell lines. These data suggest 
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that defects in the centrosome could be the underlying mechanism of CIN in 
oral cancer. The aim of this study, therefore, was to establish if centrosome 
abnormalities occurred in oral cancer. Centrosome abnormalities were first 
investigated in OSCCs and the study was then extended to examine oral 
dysplasias to determine if such defects occurred early during the genesis of oral 
cancer. Centrosome abnormalities in dysplasias were then examined in the 
context of DNA ploidy to determine if these defects were associated with the 
potential of the lesions to undergo malignant progression. 
5.2 RESULTS 
5.2.1 Centrosome identification and evaluation criteria in paraffin 
embedded archival oral tissue. 
Centrosomes in paraffin embedded oral tissues were visualised through 
immunofluorescence staining using a primary antibody against y-tubulin. A 
second primary anti-cytokeratin antibody was used to demarcate the basal and 
tumour areas from the stromal area, as the architecture of the tissue is less 
obvious when examined under high magnification. The anti-cytokeratin antibody 
also assisted in distinguishing areas of invasive tumour within the stromal area 
under high magnification. 
Similar parameters to those used in Chapter Four were used to evaluate 
centrosoma abnormalities, namely, increase in centrosome number, size and 
abnormal structure. Abnormal mitotic figures were also scored during the 
analysis as they reflect functional supernumerary centrosomes. A minimum of 
200 cells exhibiting stained centrosomes under a high-powered field were 
evaluated per sample. 98 
5.2.2 Centrosome defects in oral dysplasias and carcinomas 
A total of twenty-eight oral dysplasias, consisting of nine moderate and twenty 
severe dysplasias and a total of seventeen OSCCs, consisting of five well, six 
moderate and six poorly differentiated SCCs were analysed for centrosome 
defects. Paraffin embedded normal oral mucosa and breast ductal carcinoma in 
situ were used as negative and positive controls, respectively. Breast ductal 
carcinoma was chosen as a positive control because centrosomal abnormalities 
in this tumour have been well documented previously (Lingle et al., 2002, Pihan 
et al., 1998), 
In normal tissues, interphase cells exhibited a single or a pair of centrosomes at 
close proximity to each other (Figure 5.1), whilst a normal mitotic cell exhibited 
brightly stained bipolar centrosomes nucleating mitotic spindles (Figure 5.2A). 
By contrast, a variety of centrosome abnormalities were observed in the oral 
lesions, including centrosomes of larger diameter (Figure 5.3A), elongated 
centrosomes (Figure 5.3B) and supernumerary centrosomes (Figure 5.3C). 
Abnormal mitoses were observed in both dysplasias and SCCs (Figure 5.2B). 
Similar defects were observed in breast ductal carcinoma tissues, thus 
validating the results for the oral lesions. The frequency of centrosome defects 
in breast ductal carcinoma tissues were similar to that observed in the SCCs 
(data not shown). Normal oral tissues did not exhibit any centrosomal defects, 
indicating that centrosomal abnormalities are rare events in normal oral tissue. 
The percentage of tumour cells showing centrosomal abnormalities was low 
(2.5%-4.5%) but defects were observed in all the carcinomas analysed. 
Similarly, all twenty-eight oral dysplasias exhibited centrosomal abnormalities 
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albeit at a lower frequency (1.7%-2.3%). Amongst the different types of 
centrosomal abnormalities, alterations in centrosome size and structure were 
dominant, whilst numerical abnormalities were the least common within the 
lesions analysed in this study. 
The number of centrosome abnormalities correlated with a loss of tumour cell 
differentiation (non-parametric Kruskal-Wallis test, P<0.03; Figure 5.4), with the 
highest percentage of centrosomal abnormalities observed in poorly 
differentiated SCCs and the lowest in well-differentiated SCCs. Centrosomal 
abnormalities were significantly less common in oral dysplasias than 
carcinomas (1.8% vs 3.4%; Unpaired T-test: P<0.0001). Centrosome 
abnormalities were restricted to the dysplastic areas of the lesion and none 
were observed in the surrounding normal epithelial or stromal area. 
5.2.3 Ploidy status of oral premalignant lesions 
The results of the present study showed that there was a low level of 
centrosome abnormalities in all oral dysplasias examined. To examine whether 
these defects were associated with malignant progression, centrosome 
abnormalities were examined in the context of DNA ploidy because an 
abnormal DNA content has been shown to be a marker of malignant 
progression in oral dysplasias (Sudbo et al., 2001 a). 
The ploidy status of the oral dysplastic lesions was determined in collaboration 
with Dr. J. Sudbo and Dr. A. Reith (Norwegian Radium Hospital, University of 
Oslo, Norway), as described previously (Sudbo et a/., 2001 a). Briefly, a nuclear 
monolayer was prepared on a glass slide following trpysin digestion of two 50 
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p. m sections of paraffin-embedded oral tissues. The nucleus was stained with 
Feulgen's and periodic acid-Schiff stain and the density of the stained DNA was 
measured using high resolution image cytometry to determine the ploidy status 
of the lesion. All specimens were coded, and DNA histograms were classified in 
a blinded manner by two observers (Dr. J. Sudbo and Dr. A. Reith). A lesion 
was classified as diploid if there was only one peak (which was 2c) during the 
GO or G1 phase, if the number of 4c nuclei during the peak of the G2 phase did 
not exceed 10 percent of the total, or if the number of nuclei with a DNA content 
of more than 5c did not exceed 1 percent of the total. A lesion was defined as 
tetraploid when there was a 4c peak during the GO or G1 phase together with an 
8c peak during the G2 phase or when the number of 4c nuclei during the peak 
of the G2 phase exceeded 10 percent of the total. A lesion was defined as 
aneuploid if there were aneuploid peaks (3c, 5c, 7c, or 9c) or if the number of 
nuclei with a DNA content of more than 5c or 9c exceeded 1 percent of the total. 
The ploidy status was determined in a total of seven moderate and eighteen 
severe oral dysplasias (Table 5.1). The moderate dysplasias were 
predominantly diploid (71.4%; 5/7), whereas only 55.6% (10/18) of severe 
dysplasias were classified as being diploid. Aneuploidy was more common in 
the severe dysplasia compared to moderate dysplasia (44.4% vs. 28.6%). 
Although a slight increase in the prevalence of centrosome abnormalities was 
seen in the aneuploid lesions compared to the diploid lesions (2% vs 1.7%), the 
difference was not statistically significant. 
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5.3 SUMMARY 
This study examined centrosome abnormalities in SCCs and dysplastic lesions 
of the oral cavity. Centrosome abnormalities in terms of size, structure and 
number were seen in both SCCs and dysplasias with defects in size and 
structure being the most common. The existence of centrosome abnormalities 
in both the dysplasias and SCCs shows that defects in the centrosome are 
common in oral cancer and occur early in the disease process. Centrosome 
abnormalities appeared to be associated with disease progression because the 
percentage of cells containing abnormal centrosomes was greater in the 
tumours than in the dysplasias. Further, the percentage of centrosome 
abnormalities in SCCs correlated with a loss of tumour cell differentiation. 
DNA ploidy was used as a marker of malignant progression and was detected 
in ten of twenty-five dysplasias. In this study, aneuploidy associated strongly 
with the degree of dysplasias but there was no correlation between centrosome 
abnormalities and ploidy. A small increase in centrosome abnormalities was 




Figure 5.1 Centrosomes in paraffin embedded normal oral tissue 
Immunofluorescence image of a (A) single or (B) a pair of centrosomes at close 
proximity to each other, exhibiting punctate morphology, as usually 
observed in 
normal oral tissues. Centrosomes were 
detected using primary antibody against 
y-tubulin and the epithelial cells were 
detected using antibody against 
cytokeratin. The primary antibodies were 
detected using Cyc3 (red; y-tubulin) 
and FITC (green; cytokeratin) conjugated secondary antibodies. 
The nuclei 
were counterstained with DAPI (blue; x1000). 
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Figure 5.2 Mitotic figures observed in oral carcinomas 
Cells undergoing (A) normal mitosis exhibit distinct brightly stained bipolar 
mitotic spindles, whilst (B) abnormal mitosis consists of multipolar spindles 
(x2000). Centrosomes were detected using primary antibody against y-tubulin 
and the epithelial cells were detected using antibody against cytokeratin. The 
primary antibodies were detected using Cyc3 (red; y-tubulin) and FITC (green; 
cytokeratin) conjugated secondary antibodies. The nuclei were counterstained 





Figure 5.3 Centrosomal abnormalities observed in oral carcinomas 
Centrosome abnormalities included (A) an increase in size, (B) alterations in 
shape resulting in elongated centrosomes and (C) increase in centrosome 
number (x2000). Centrosomes were detected using primary antibody against y- 
tubulin and the epithelial cells were detected using antibody against cytokeratin. 
The primary antibodies were detected using Cyc3 (red; y-tubulin) and FITC 
(green; cytokeratin) conjugated secondary antibodies. The nuclei were 
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Figure 5.4 Centrosome abnormalities correlate with a loss of 
differentiation in oral SCCs 
The presence of centrosome abnormalities was evaluated in a minimum of 200 
cells per sample. The results represent the mean (± standard deviation) 
percentage of cells exhibiting centrosome abnormalities in well (W), moderate 
(M) and poorly (P) differentiated carcinomas. Statistical analysis (Kruskal- 
Wallis, P<0.03) showed a significant correlation between centrosome defects in 
carcinomas and loss of tumour cell differentiation. 
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Table 5.1 Ploidy status of moderate and severe oral dysplaslas 
Dysplastic lesions Moderate Severe 
Total 7 18 
Ploidy 
Diploid 5/7 (71.4%) 10/18 (55.6%) 
Aneuploid 2/7 (28.6%) 8/18 (44.4%) 
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CHAPTER SIX 
THE DEVELOPMENT OF PHIP RESISTANCE IN IMMORTALISED 
HUMAN NORMAL ORAL KERATINOCYTES RESULTS IN 
STABLE CHROMOSOME NUMBER ALTERATIONS BUT DOES 




Aneuploidy, or CIN, is ubiquitous and a dominant phenotype in cancer. Based 
on the presence of aneuploidy in premalignant lesions of a variety of cancers, 
CIN has been suggested to occur early and drive tumour progression (Pihan et 
al., 2003). Although defects in mechanisms involving growth inhibition, DNA 
repair and chromosome segregation have been implicated in CIN, it is unclear 
whether such abnormalities are a cause or consequence of CIN. The 
development of an in vitro model of CIN would greatly facilitate the elucidation 
of the mechanisms involved in CIN and how they contribute towards 
tumorigenesis. 
In the past, many studies have employed chemicals to demonstrate the ability 
of carcinogens to induce or select for aneuploidy. However, these studies were 
carried out either in rodent or cancer cell lines, which are naturally more 
susceptible to chemical manipulations. For example, treatment of the colorectal 
carcinoma cell line, HCT116, with the carcinogen PhIP was shown to induce 
CIN (Bardelli et al., 2001). Normal human cells have historically proven to be 
difficult to transform in part because they have a short life span in culture (Rhim, 
1991), but the development of immortalised human oral keratinocytes by the 
expression of hTERT, the catalytic subunit of the telomerase enzyme (Dickson 
et al., 2000) means that essentially normal cells can now be used. 
The aim of the present study was to determine if aneuploidy could be induced in 
an immortalised human normal oral keratinocyte cell line, OKF6/TERT-1, using 
PhIP. Having determined that the development of PhIP resistance was 
associated with the acquisition of consistent chromosomal gains, the study was 
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extended to determine whether the induction of carcinogen resistance produced 
cells that were resistant to DNA damage. 
6.2 RESULTS 
6.2.1 Generating PhIP-resistant clones 
To generate PhIP-resistant cells, the immortalised normal epithelial cell line 
OKF6/TERT-1 was initially treated with 50 . tM activated PhIP for 3 hours. 
Approximately 1 x10-6-2x10 cells survived the first treatment. After achieving 
exponential growth, the surviving cells were retreated with 50 µM PhIP and 
clonal populations of surviving cells were isolated. To identify PhIP-resistant 
clones, the cells were retreated with 50 µM PhIP and the plating efficiency was 
normalised against OKF6/TERT-1 parental cells treated with or without 
activated PhIP. Approximately 0.2x10"5-1x10"5 cells survived the final PhIP 
treatment. Since PhIP treated parental cells frequently demonstrated very low 
colony forming efficiency, clones that formed more colonies compared to the 
parental cells following PhIP treatment were considered PhIP-resistant. From a 
total of thirty clones originally isolated, only four (clones 13,16,18 and 20) 
exhibited increased resistance to PhIP and were chosen for further analysis 
(Figure 6.1). 
6.2.2 Cytogenetic analysis of PhIP-resistant clones. 
To examine whether the development of PhIP resistance resulted In 
chromosomal imbalances, CGH analysis was performed on both low (4-5) and 
high (22-25) passage PhIP-resistant clones. Chromosomal losses and gains as 
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observed by CGH, in the parental OKF6-TERT/1 and PhIP-resistant clones are 
shown in Table 6.1. 
The parental OKF6/TERT-1 cells exhibited gains of 1g22-qter and chromosome 
5 and loss of 9p13-pter, associated with the acquisition of an immortal 
phenotype (Dickson et al., 2000). Compared to parental OKF6/TERT-1 cells, all 
PhIP-resistant clones (clone 13,16,18 and 20) showed gains of chromosome 
8,9p21/22-qter and 20 at lower passage. An additional gain of chromosome 7 
was seen in three of four clones (clone 13,16 and 18) at higher passage. Clone 
13 also exhibited an additional possible loss of 1q21-22, chromosome 2,3 and 
17. The consistency in the chromosomal alterations observed in the different 
PhIP-resistant clones suggests that the development of PhIP resistance in 
immortalised human oral keratinocytes resulted in aneuploidy in terms of 
consistent chromosomal gains and not a dynamic unstable karyotype typical of 
CIN. 
6.2.3 Response to DNA damage In PhIP-resistant clones 
Since no widespread CIN was seen in the OKF6-TERT/1 PhIP-resistant clones, 
we therefore hypothesised that the development of PhIP resistance was 
associated with resistance to other forms of DNA damage. Therefore, the 
cellular response to irradiation induced DNA damage in terms of cell viability, 
induction of apoptosis, activation of the p53 pathway and cell cycle arrest was 
assessed in both parental OKF6/TERT-1 cell lines and PhIP- resistant clones. 
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6.2.3.1 Cell viability 
To analyse cell viability following DNA damage, MTT assays were performed 48 
and 72 hours following 5Gy irradiation of parental OKF6/TERT-1 and the PhIP 
resistant clones. 
Irradiation of the cells resulted in a similar reduction in yield of attached cells in 
both parental and PhIP resistant clones after 48 and 72 hours, indicating that 
PhIP resistant clones were no more radiosensitive than the parental cell line to 
irradiation (Figure 6.2). 
6.2.3.2 Apoptosis 
To determine the apoptotic response in the parental OKF6/TERT-1 and the 
PhIP resistant clones, FAGS analyses were performed after 24,48 and 72 
hours following 5Gy irradiation. Apoptotic cells were detected using a FITC- 
conjugated annexin-V antibody. 
A high proportion of early apoptotic cells were seen in both unirradiated and 
irradiated culture at all time points, which may have been due to enzymatic 
detachment of cells prior to FAGS analysis. Nevertheless, an increase in 
annexin/propidium iodide positive signals signifying late apoptotic cells was 
observed 24 hours after irradiation in both parental OKF6/TERT-1 cells (Figure 
6.3) and the PhIP-resistant clones (Figure 6.4). The lack of floating apoptotic 
cells in irradiated cultures of both parental and the PhIP-resistant clones, 
concurrent with an increase in early and a reduction in late apoptotic cells 
observed during FACS analysis, 48 and 72 hours following irradiation, suggests 
that these cells did not undergo apoptosis but re-entered the cell cycle. 
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6.2.3.3 p53 pathway 
The integrity of the p53 pathway was analysed due to its importance as a 
regulator of cell cycle and apoptosis. Induction of the p53 protein and its 
transcriptional targets, MDM2, and p21 was assessed by western blot analysis 
in both parental OKF6/TERT-1 cell lines and the PhIP resistant clones at 0,2,4, 
6 and 24 hours following 5Gy irradiation. 
In both the parental OKF6/TERT-1 cells and PhIP resistant clones, p53 was 
induced within 2 hours of irradiation and the induction of p21 and MDM2 was 
seen within 4 hours following irradiation, indicating that the p53 pathway was 
functional. A representative western blot of p53, p21 and MDM2 for the PhIP 
resistant clone 18 is shown in Figure 6.5. 
6.2.3.4 Cell cycle 
To determine if the clones harbour defects in the ability to arrest In response to 
DNA damage, FACS analysis of cell cycle arrest was performed In both 
parental OKF6/TERT-1 and PhIP resistant clones, 24 and 48 hours following 
irradiation. Cell cycle analyses of parental OKF61TERT-1 is shown in Figure 6.6 
and a representative PhIP resistant clone 18 is shown In Figure 6.7. 
Irradiated OKF6-TERT/1 cells exhibited cell cycle arrest at 24 hours following 
5Gy radiation. The cells exited the arrest after 48 hours following irradiation and 
exhibited a similar FACS profile as asynchronous cultures (Figure 6.6). Similar 
arrest was observed in the PhIP resistant clones and the FACS profile of clone 
18 is shown in Figure 6.7. 
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6.3 SUMMARY 
This study examined the effect of treating an immortalised normal oral 
keratinocyte cell line, OKF6ITERT-1, with PhIP, a bulky adduct forming agent 
that has been shown previously to induce CIN in carcinoma cells (Bardelli of al., 
2000). 
CGH analysis of PhIP resistant clones demonstrated a consistent gain of 
chromosomes 8,9p21/22-qter and 20 in all clones at lower passage and an 
additional gain of chromosome 7 in three of the clones in higher passage, 
indicating that PhIP treatment resulted in consistent chromosomal alterations 
and not a dynamic CIN. It seems likely that the consistent gains observed in the 
PhIP-resistant clones are specific and sufficient to confer resistance to PhIP. 
Examination of the cellular response to irradiation-induced DNA damage 
demonstrated that both parental OKF6/TERT-1 and PhIP resistant clones 
exhibited similar growth inhibitory and apoptotic responses, have an intact p53 
pathway and are capable of cell cycle arrest following irradiation. The 
similarities between the parental cells and PhIP resistant clones in their 
response to DNA damage suggests that the induction of PhIP resistance is not 
also associated with resistance to irradiation induced DNA damage. 
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Figure 6.1 Resistance to PhIP 
FF 
To identify PhIP resistant clones, 106 cells of individual PhIP clones were 
treated with 50µM PhIP and stained with methylene blue after 14 days. 
OKF6/TERT-1, parental cells were treated without PhIP (A) and with 50µM PhIP 
(B) as controls. The plating efficiency of the PhIP clones was normalised to the 
plating efficiency of PhIP treated control cells to identify PhIP resistant clones. 
Clones that formed more colonies in comparison to PhIP treated parental cells 
(B) were considered PhIP-resistant (C-F). PhIP treatment of the clones was 
repeated in order to confirm resistance to the carcinogen. 
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Table 6.1 Chromosomal alterations in PhIP resistant clones 
Low passage Additional gains or losses at high passage 
Parental 1g22-gter. 5 9p13-pter 
OKF6/TERT-1 
PhIP clones 
Clone 13 1g23-qter, 5,8,9,20 7.9p22-gter, possible loss of 1q21-1q22.2,3,17 
Clone 16 1 q23-qter, 5,8,9p22-qter, 20 7 
Clone 18 1g21-qter, 5,8,9p22-qter, 20 7 
Clone 20 1g24-qter, 5,8,9p21-gter, 20 None 
CGH was performed on both low and high passage PhIP resistant clones. 
Relative to the parental cell line, OKF6/TERT-1, the PhIP resistant clones 
exhibited a consistent gain (green) of chromosome 8,9p21/22-qter and 20 at 
low passage and 7 at high passage. Clone 13 also exhibited additional losses 
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Figure 6.2 MTT assay for analysis of cell viability following irradiation 
MTT assay were performed 48 and 72 hours following 5Gy irradiation. No 
difference in cell yield was seen between parental OKF6/TERT-1 (T1) and PhIP 
resistant clones at either time point following irradiation. Data points reflect the 



















Figure 6.3 FACS analysis of apoptotic cells following irradiation of 
OKF6/TERT-1 parental cells 
Cells were stained with FITC conjugated-annexin antibody and/or propidium 
iodide and the presence of apoptotic cells were examined in (i) unirradiated 
cells (ii) 24, (iii) 48 and (iv) 72 hours following 5Gy irradiation. Cells stained with 
annexin only (A) indicate early apoptotic cells, propidium iodide only (PI) 
indicate necrotic or dead cells and cells stained with both annexin and 
propidium iodide (A/PI) indicate late apoptotic cells. In contrast to unirradiated 
control, an increase in late apoptotic cells can be seen 24 hours following 
irradiation. These cells do not die but go on to cycle after 48 and 72 hours 
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Figure 6.4 FACS analysis of apoptotic cells following irradiation of a 
PhIP resistant clone 18. 
PhIP resistant clone 18 cells were similarly stained with FITC conjugated- 
annexin antibody and/or propidium iodide. By contrast to the (i) unirradiated 
PhIP resistant clone 18 cells, (ii) an increase in late apoptotic cells was seen 24 
hours after irradiation, which diminished in number after (iii) 48 and (iv) 72 hours 
following irradiation. 
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Figure 6.5 Western blot analysis of p53, p21 and MDM2 induction, in 
PhIP resistant clone 18 following 5Gy irradiation 
p53 was induced within 2 hours of irradiation and maintained at a high level in 
comparison to unirradiated control. Both p21 and MDM2 were also induced 
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Figure 6.6 FACS analysis of cell cycle arrest in parental OKF6/TERT-1 
cells 
Unirradiated parental cells exhibited an asynchronous cell cycle profile. The 
cells arrested at both GO/G1 and G2/M phase arrest 24 hours after irradiation 
(B), exited arrest and began cycling to create an asynchronous population of 
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Figure 6.7 FACS analysis of cell cycle arrest in PhIP resistant clone 18 
Unirradiated PhIP resistant cells exhibited an asynchronous cell cycle profile. 
The cells exhibited both GO/G1 and G2/M phase arrest 24 hours after irradiation 
(B), exited arrest and began cycling after 48 hours following irradiation. The 







Evidence is accumulating to indicate that CIN occurs early in the neoplastic 
process and drives tumour progression (Shih et al., 2001; Nowak et al., 2002; 
Komarova et al., 2003). The presence of aneuploidy in premalignant lesions of 
the oral cavity has been shown to correlate with malignant transformation 
(Sudbo et al., 2001a; b), which suggests that CIN might facilitate the 
progression of oral cancer. The present study was initiated to investigate the 
mechanisms responsible for CIN in oral carcinogenesis. 
This study examined the integrity of the chromosome segregation machinery, 
namely the mitotic checkpoint (Hartwell, 1992), the post-mitotic tetraploidy 
checkpoint (Andreassen et al., 2001 a) and centrosomes (Ghadimi et al., 2000) 
in human oral cancer. The work was made possible by the availability of a 
series of human OSCC-derived cell lines that had previously been shown to 
harbour numerical and structural chromosome alterations (Patel et at, 1993). 
Having determined that centrosome abnormalities were prevalent in vitro, the 
study was extended to examine the centrosome status of archival paraffin- 
embedded oral carcinomas and dysplasias; centrosome abnormalities in the 
dysplasias were also analysed in the context of DNA ploidy to examine if such 
abnormalities might be associated with malignant progression. In parallel 
studies, human immortalised normal oral keratinocytes were treated with the 
carcinogen PhIP in an attempt to develop an in vitro model of CIN. 
For ease of interpretation, the Discussion has been subdivided such that 
consideration is given separately to the analysis of defects in the chromosomal 
segregation machinery in vitro, the analysis of centrosome abnormalities and 
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DNA ploidy in oral tissues in vivo and the development of an in vitro model of 
CIN in human immortalised normal oral keratinocytes. Proposals for future 
studies are included at the end of the Discussion. 
7.2 ANALYSIS OF THE CHROMOSOMAL SEGREGATION MACHINERY 
IN HUMAN OSCC-DERIVED CELL LINES 
7.2.1 Genetic instability in human OSCC-derived cell lines 
The H-series of OSCC-derived cell lines have been shown previously to exhibit 
structural chromosomal aberrations including a high frequency of consistent 
chromosome breaks on chromosome 1,7,8,9,11 and X and the formation of 
isochromosomes 8,9 and 11 (Patel et al., 1993). Further, the cell lines also 
harboured numerical chromosomal aberrations; H103 exhibited a modal 
chromosome number of 41, whilst H157, H314, H357, H376, H400 and H413 
exhibited a modal chromosome number that ranged between 72-91 (Patel et al., 
1993). 
Although CIN and MIN have been suggested to be mutually exclusive (Lengaur 
et al., 1998), exceptions to this rule have been reported (Ghadimi et al., 2000). 
MIN cell lines are thought to be chromosomally stable and exhibit relatively few 
of the chromosome segregation defects related to the CIN phenotype (Ghadimi 
et al., 2000; Tighe et al., 2001). It was essential, therefore, to exclude the 
presence of MIN in the OSCC-derived cell lines to be used in this study. MIN 
has been shown to result from disruption of the MMR pathway and this has 
been mainly attributed to mutations of the hMLHI and hMSH2 genes 
(Buermeyer et al., 1999; Jiricny and Lahti, 2000). The results of the present 
study demonstrate that all seven OSCC-derived cell lines expressed both 
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hMLH1 and hMSH2 proteins, which strongly indicates that their MMR pathway 
is intact. Taken together with the chromosome alterations observed in these cell 
lines, these results indicate that the OSCC-derived cell lines used in this study 
exhibit exclusively CIN and not MIN. The data are entirely consistent with the 
observation that MIN is rare in oral cancer (Ishwad et al., 1995). 
7.2.2 Analysis of the mitotic and tetraploidy checkpoints in human 
OSCC-derived cell lines 
7.2.2.1 Mitotic checkpoint 
The mitotic checkpoint functions to monitor the process of kinetochore capture 
of metaphase chromosomes by spindle microtubules during mitosis to ensure 
an error free and even segregation of chromosomes (Skibbens et at, 1998). 
Loss of this checkpoint has been shown to promote aneuploidy, result in 
chromosome missegregation and contribute to genomic instability in human 
cancers (Wassmann et al., 2001). 
The present study examined the integrity of the mitotic checkpoint in the H- 
series of OSCC-derived cell lines. The cells were treated with the microtubule 
depolymerising drug, nocodazole and the mitotic checkpoint examined following 
FAGS analyses of the cell cycle and by quantification of mitotic indices. Analysis 
of the cell cycle after 18 hours of nocodazole treatment demonstrated a strong 
G2/M arrest in all the OSCC-derived cell lines, in a similar manner to the control 
cell line HCTI 16, indicating that the mitotic checkpoint was intact in these cells. 
Analysis of the mitotic indices, however, indicated a transient arrest of cells in 
mitosis in all of the cell lines after 18-24 hours of nocodazole treatment but only 
H357 and H400 cells behaved the same as control HCT116 cells; the mitotic 
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indices of the remaining five cell lines were lower than the control (37%-55% vs 
>_70%). The percentage of cells in mitosis as determined by 
immunocytochemical staining for phospho-histone H3 was consistently lower 
than that indicated by FACS analysis. The discrepancy between the results 
obtained using these two techniques is likely to be due to the fact that the FACS 
analyses detected mitotic cells based on DNA content, whilst 
immunocytochemical analyses with the anti phospho-histone H3 antibody 
detects phosphorylated histone H3 proteins, which accumulate during mitosis. 
The percentage of cells arrested at G2/M as determined by FAGS analysis 
includes cells at the end of S-phase, G2 and M phase, whilst the mitotic index 
analysis enables visualization and scoring of cells specifically in mitosis and, 
therefore, is a more accurate estimate of the number of mitotic cells. Taken 
together, the results indicate that the mitotic checkpoint is fully functional in two 
(H357 and H400) of the OSCC-derived cell lines and attenuated in the 
remaining five cell lines. 
The results of the present study contrast with reports describing defective 
mitotic checkpoints in colon (Cahill et al., 1998) and breast (Moon et al., 2002) 
cancer cell lines but are supported by the only other study to examine the 
mitotic checkpoint in head and neck squamous cell carcinoma (HNSCC) cell 
lines, which reported a similar attenuation of the checkpoint (Minhas at al., 
2003). Such discrepancies are likely to be due to inconsistent interpretation of 
the mitotic indices of cell lines [eg. Tighe et al., (2001) vs Cahill at al., (1998)]. 
Further, misinterpretation of the GO/GI arrest and the consequential reduction 
in mitotic cells arrested at G2/M observed in some cell lines has been taken to 
indicate a defective mitotic checkpoint (Yoon et al., 2002); this GO/GI arrest has 
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been shown to be due to a nocodazole dose-dependent ability of some cell 
lines to arrest at GO/G1 and/or G2/M phase of the cell cycle rather than due to a 
cancer-associated checkpoint loss (Blajeski et a/., 2002). 
It has been proposed that a compromised mitotic checkpoint could mediate 
subtle rates of chromosome missegregation that is compatible with cell viability 
(Babu et al., 2003; Michel et al., 2001). In support of this theory, mutations in 
known spindle checkpoint genes are rare in human tumours (Cahill of al., 1998) 
and complete suppression of the mitotic checkpoint has been demonstrated to 
result in lethality due to massive chromosome loss (Kops of al., 2004). Further, 
studies have showed an elevated rate of chromosome missegregation in 
Bub3+'" mice (Babu et al., 2003) and Mad2+'" human cancer cells (Michel et al., 
2001) and a compromised mitotic checkpoint in ovarian cancer cells with 
lowered expression of Mad2 (Wang of al., 2002). These results indicate a role 
for haplo-insufficiency of mitotic checkpoint genes in compromising the fidelity 
of the checkpoint. The expression status of the mitotic checkpoint genes in the 
OSCC-derived cell lines used in the present study, however, is not known. 
7.2.2.2 Tetraploidy checkpoint 
The tetraploidy checkpoint is a post-mitotic checkpoint (Lanni and Jacks, 1998) 
that functions to elicit a G1 arrest in cells that exit mitosis with a tetraploid DNA 
content (Andreassen et al., 2001a). In the present study, analysis of the cell 
cycle after 36 hours of nocodazole treatment indicated DNA reduplication in a 
high percentage of H357 and H376 cells, suggesting a defect in the ability of the 
cells to arrest with a tetraploid DNA content. Therefore, the tetraploidy 
checkpoint was assessed by FACS analysis of the cell cycle after releasing 
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cells from treatment with the cytokinesis inhibitor, DCB. The H400 cell line was 
chosen as a control for this assay, as it exhibited G2/M arrest during prolonged 
nocodazole treatment 
Cell cycle analysis of DCB treated H400 cells showed that the cells were able to 
maintain G2/M arrest 18 hours after release into drug free medium. By contrast, 
a polyploid cell population was beginning to emerge in H357 and the presence 
of a polyploid cell population was evident in H376 after 18 hours release into 
drug free medium. However, the H400 cells exhibited formation of polyploid 
population of cells, similar to H357 and H376 cells, after 36 hours release from 
DCB treatment. This could potentially be attributed to the mutation(s) in the p53 
gene harboured by all the OSCC-derived cell lines (Yeudall et 8/., 1995), as p53 
is thought to be important for maintenance of a post-mitotic arrest (Lanni and 
Jacks, 1998; Andreassen et al., 2001 a). The formation of a polyploid population 
of cells in all cell lines after prolonged release from DCB treatment, however, 
indicates that the checkpoint might also be attenuated in the H400 cells. 
It is important to note that our understanding of the tetraploidy checkpoint is in 
its infancy. Recent evidence suggests that the arrest observed following the 
mitotic exit of tetraploid cells, which was reported to be caused by the 
tetraploidy checkpoint (Andreassen et al., 2001 a), was due to disorganization of 
the actin cytoskeleton by the high dose of DCB used that persists even after 
drug removal (Uetake et al., 2004). Considering the controversy surrounding the 
tetraploidy checkpoint, this experiment, therefore, needs to be repeated using 
control cells with intact p53 and the ability of tetraploid cells to arrest should be 
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ascertained following induction of tetraploidization using methods other than 
inhibition of cytokinesis. 
7.2.3 Analysis of centrosome abnormalities in human OSCC-derlved cell 
lines 
Although an impaired mitotic checkpoint is compatible with a low level of 
chromosome loss, it does not provide an explanation for the high chromosome 
number alterations observed in these cell lines. It is likely, therefore, that 
alternative mechanisms are also responsible for the CIN observed in these cell 
lines. The centrosome is the major microtubule-organizing centre (MTOC) of 
animal cells and its ability to form bipolar spindles is vital for accurate 
chromosome segregation into progeny cells. Centrosome defects have been 
suggested to drive CIN via their ability to mediate multipolar spindle formation 
and the consequential missegregation of chromosomes (Brinkley, 2001). 
The results of this study showed that five of seven OSCC-derived cell lines 
exhibited centrosome abnormalities in terms of centrosome number, size and 
localization, suggesting that centrosome defects are common in oral cancer. 
This is the first study to examine centrosome abnormalities in OSCC-derived 
cell lines and the results are consistent with a number of reports using tumour- 
derived cell lines from a variety of other cancers (Ghadimi at al., 2000; Sato at 
al., 1999; 2001; D'Assoro et al., 2002). The spectrum of centrosome defects 
observed in this study, namely, supernumerary centrosomes, increase in 
centrosome size, mislocalised centrosomes, abnormal mitoses and dispersed 
pericentrin staining are similar to those reported in other studies (Sato at al., 
1999; Ghadimi at al., 2000). Importantly, centrosome defects occurred mainly in 
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the aneuploid cell lines used in this study, whilst the diploid HCT116 cells 
showed centrosome profile similar to normal cells; a similar correlation between 
centrosome abnormalities and aneuploidy has been reported in colon cancer 
cell lines (Ghadimi et al., 2000). The increase in centrosome size due to 
increased pericentrin staining and dispersed pericentrin staining observed in the 
OSCC-derived cell lines has been suggested previously to cause accumulation 
of excess pericentriolar material, which might be associated with a highly 
anaplastic phenotype (Lingle and Salisbury, 1999). Breast tumours with excess 
pericentriolar material have been found to have higher frequency of abnormal 
mitosis (Lingle and Salisbury, 1999). It seems possible, therefore, that the 
excess centrosomes and pericentriolar material seen in the OSCC-derived cell 
lines could co-operate to perpetuate abnormal mitoses resulting in the altered 
chromosome number previously reported in these cell lines (Patel et al., 1993) 
It is interesting that H357 and H376 cells, which exhibited a centrosome profile 
similar to that seen in normal cells, also exhibited DNA reduplication following 
prolonged nocodazole arrest (Chapter Three). It is tempting to speculate that 
this could be caused by the specific p53 mutations carried by these cells, as 
studies have shown that conformational mutants of p53 can abrogate the 
spindle checkpoint leading to polyploidization (Gualberto et al., 1998) and have 
varying effects on the centrosome (Tarapore et al., 2001). Characterization of 
the effect of the p53 mutations, in H357 and H376 cells might shed some light 
upon how the protein regulates these two different aspects of the chromosome 
segregation machinery. 
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In addition to its role in chromosome segregation, the centrosome also 
coordinates other microtubule-related functions such as cell shape and polarity, 
through its control of number, polarity and distribution of microtubules (Fry et al., 
2000). Based on the hypothesis that cells showing a high level of centrosome 
hyperamplification would exhibit abnormalities in microtubule nucleation, 
centrosome function was examined in the present study by analysing the 
capacity of the centrosome(s) to nucleate microtubules following nocodazole- 
induced microtubule depolymerization. The results demonstrated a varied 
response amongst the OSCC-derived CIN lines, with 18.45% - 82.35% of cells 
nucleating microtubules 2 minutes after release from nocodazole. However, 
despite the delayed microtubule nucleation seen in some cell lines, the process 
was completed by 30 minutes in all cell lines. This observation is in contrast to 
the work by Ghadimi at al. (2000), who showed that centrosomes of aneuploid 
cells exhibited prolonged recovery time compared to that of diploid cells. The 
significance of the delayed microtubule nucleation observed in the present 
study in terms of centrosome function is not known. 
During the assessment of centrosome function, microtubule nucleation 
consistently originated from one or two centrosomes only, despite the presence 
of supernumerary centrosomes in some cells. This suggests that not all 
supernumerary centrosomes have an equal potential to nucleate microtubules. 
Whether this inability of the supernumerary centrosomes to nucleate 
microtubules is restricted to the nucleation of interphase microtubules is not 
known, as they do nucleate microtubules during multipolar mitosis. The 
excessive microtubule nucleation and unorganised microtubule network 
observed in H413 and H357 cells following 2 minutes release from nocodazole 
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suggests that aspects other than the ability to nucleate microtubules, such as 
the ability to monitor the number of microtubules nucleated by the centrosome, 
might be compromised in some cell lines. Consistently, Lingle et al. (2002) 
showed that excessive microtubule nucleation, as determined by an increase in 
microtubule numbers nucleated by tumour centrosomes, correlated with a loss 
of tissue differentiation in breast tumours. 
It has been assumed that cell death is the likely fate of progeny cells generated 
through an abnormal mitosis but no work has been carried out to support this 
hypothesis. In the present study, centrosome stability was examined in H413 
cells because a high percentage of these cells exhibited centrosome 
abnormalities. The investigation of centrosome stability in H413 cells was 
initially undertaken to examine the fate of cells following an abnormal mitosis by 
video-microscopy of CETN2-EGFP tagged centrosomes. During the course of 
this work, cells with normal and abnormal number of centrosomes were 
observed in cloned populations of CETN2-EGFP transfected H413 cells. To 
ensure that this is not an artefact of transfection, cloned untransfected H413 
cells were analysed and were shown to exhibit a similar combination of cells 
with normal and abnormal centrosome number. These observations suggest 
that centrosomes in H413 cells with high centrosomal abnormalities could be 
inherently unstable and this instability is apparent in cells with normal looking 
centrosomes. It is possible that centrosome instability could result in the 
formation of further cells containing centrosome abnormalities, which has 
potential to drive CIN through chromosome missegregation. There is some 
experimental support for this proposal because chromosome missegregation 
has been shown to be an incessant process, as observed through structural 
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variation in marker chromosomes in clonal populations of cancer cells (Reshmi 
et al., 2004). Further evidence show that defects in chromosome segregation 
are intrinsic and inherited characteristics of the whole cell population in general 
and not just a subpopulation of cells (Reing et al., 2004). The work to elucidate 
the fate of the progenies of an abnormal mitosis, using the CETN2-EGFP 
tagged H413 cells, is on going. 
The question remains as to how cells survive with high centrosome numbers. A 
number of possible mechanisms have been proposed to explain this 
phenomenon. It is possible that somatic cells can use a centrosome 
independent pathway for spindle formation that is strong enough to drive bipolar 
spindle assembly (Khodjakov at al., 2000). Alternatively, evidence of 
centrosomes clustering at the spindle poles was observed in the OSCC-derived 
cell lines used in this study, which suggests that supernumerary centrosomes 
coalesce to form a bipolar spindle (Lingle at al., 1999). There is also some 
support for the possible acquisition of mutation(s) or clonal expansion of cells 
that have accrued mutation(s) that suppress centrosome abnormalities in order 
to enable accurate segregation of an acquired karyotype that is most conducive 
for survival in vitro (Chiba at al., 2000). Finally, the hypothetical 'deamplification 
of centrosomes', whereby all but two dominant centrosomes are inactivated 
and/or eliminated, may also suppress the negative effects of centrosome 
hyperamplification (Brinkley, 2001). 
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7.3 ANALYSIS OF CENTROSOME ABNORMALITIES AND DNA PLOIDY 
IN ORAL DYSPLASIAS AND SCCs. 
Centrosome abnormalities are common in many human cancers (Pihan et al., 
1998) and have been associated with tumour aggressiveness (D'Assoro et al., 
2002). Centrosome defects have been suggested to contribute to cancer 
development through the generation of CIN as these defects frequently coexist 
with aneuploidy in a variety of tumour types (Gustafson et aL, 2000, Sato et al., 
2001, Jiang et al., 2003). 
The results of Chapter Four demonstrated that centrosome abnormalities are 
common in OSCC-derived cell lines. In order to determine whether such 
abnormalities occur in vivo, a similar study was undertaken to examine 
centrosomes in oral premalignant and malignant tissues. The results 
demonstrate that centrosome abnormalities occur in both oral dysplasias and 
SCCs and were manifest as an increase in centrosome size, number and 
structural defects such as elongated centrosomes. These abnormalities are 
consistent with those documented in other studies (Pihan at aL, 1998; Jiang at 
al., 2003; Pihan at at, 2003). Interestingly, increase in centrosome size and 
structural defects such as elongated centrosomes were observed more 
frequently in vivo, in contrast to the more prevalent numerical abnormalities 
observed in cultured cells. 
In the present study, 100% (17/17) of the SCCs examined exhibited centrosome 
abnormalities, demonstrating that centrosome abnormalities are prevalent in 
oral cancer. The percentage of tumour cells exhibiting these abnormalities 
correlated significantly with increasing histological grade, whereby well 
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differentiated tumours exhibited the lowest (2.5%), whilst poorly differentiated 
tumours exhibited the highest percentage of cells (4.5%) with centrosome 
abnormalities. Similarly, a high prevalence of centrosome abnormalities and an 
increased incidence of centrosome abnormalities in high-grade tumours have 
also been reported in oral (Carroll et a!., 1999; Gustafson et a!., 2000) and 
various other cancers (Pihan et a!., 1998; Sato et al., 1999; Pihan et a!., 2001; 
2003; Jiang et a!., 2003). The correlation between centrosome abnormalities 
and a loss of tumour cell differentiation suggests that centrosome abnormalities 
might contribute to tumour aggressiveness (Sparano et a!., 2004). It has been 
proposed that centrosome dysfunction could cause modification of the 
microtubule cytoskeleton leading to cellular disorganization, creating cells that 
are predisposed to additional changes that could lead to aggressive tumour 
development (Pihan et a!., 2001) and tumour recurrence (Gustafson et a!., 
2000). 
Examination of centrosome abnormalities in the premalignant tissues showed 
that 100% (28/28) of oral dysplasias exhibited centrosomal abnormalities, 
although the percentage of cells exhibiting these abnormalities were low (1.7%- 
2.3%). The present study is the first to examine centrosome abnormalities in 
oral dysplasias and the results indicate that these abnormalities might occur 
early in oral cancer. To investigate whether centrosome abnormalities might be 
associated with malignant progression, these defects were examined in the 
context of DNA ploidy. It has been shown previously that aneuploldy is a 
reliable marker of malignant transformation in oral dysplasias (Sudbo et a!., 
2001a; 2001b). In the present study, there was only a slight Increase in the 
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prevalence of centrosome abnormalities in the aneuploid compared to the 
diploid lesions (2% vs 1.7%) and the difference was not statistically significant. 
In the present study, 10/25 (40%) of dysplasias were classified as aneuploid, 
which is higher than that reported (17%) in the cohort of patients used by Sudbo 
et al. (2001 a). Whether these differences reflect low sample numbers, the high 
number of severe dysplasias used and/or population-based differences is 
unknown. It is cautionary, however, to note that the findings of Sudbo and co- 
workers have not been verified in other laboratories. A longitudinal study using 
dysplasias with known outcomes is required to examine any association 
between centrosome abnormalities and malignant progression. 
Due to the presence of centrosome abnormalities in all dysplasias regardless of 
ploidy status, it remains a possibility that centrosome abnormalities do not 
correlate with aneuploidy in early lesions of oral cancer. Support for this 
proposal comes from the observation that centrosome abnormalities have been 
observed in grade 1, diploid bladder cancer cells (Jiang et a!., 2003) and 
centrosome defects have been detected in carcinomas in situ that lacked CIN 
(Pihan et al., 2003). This is in contrast to the many studies that have reported a 
strong correlation between centrosome abnormalities and aneuploidy (Jiang at 
al., 2003; Pihan et al., 2001; Lingle at a!., 2002; Pihan et a!., 1998). These 
interpretations were, however, based on the analyses of centrosome 
abnormalities and aneuploidy in malignant tumours and metastatic lesions 
(Jiang et al., 2003; Pihan et a!., 2001; Lingle et a!., 2002; Pihan at al., 1998) in 
which both phenotypes are found to be highly prevalent. It is possible that the 
centrosome abnormalities observed in diploid dysplaslas in the present study 
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could have arisen as a consequence of the deregulated cellular growth and 
differentiation that is associated with the dysplastic phenotype. 
It remains a possibility that centrosome abnormalities could potentially drive oral 
cancer progression by perpetuating CIN, based on the concomitant presence of 
centrosome abnormalities with abnormal mitoses in the oral lesions. It is also 
likely that additional mutations might be required before the centrosome 
abnormalities observed in the dysplasias could actively drive CIN and oral 
cancer progression. An increase in centrosome abnormalities was observed in 
this study during transition from dysplasias (1.7%-2.3%) to SCCs (2.5%-4.5%). 
The transition to the invasive phenotype has also been shown to be the period 
during which inactivation of p53 usually occurs in oral cancer (Shanavaz of aL, 
2000) and centrosome abnormalities have been shown to occur in tandem with 
p53 inactivation in oral carcinomas (Carroll at al., 1999) This suggests that 
inactivation of p53 might co-operate with centrosome defects leading to CIN 
and could potentially provide an explanation as to why the correlation between 
centrosome abnormalities and, aneuploidy is more prominent during the later 
stages of cancer (Jiang at al., 2003; Pihan at aL, 2001; Lingle of al., 2002; 
Pihan at al., 1998). Centrosome abnormalities have also been observed 
following inactivation of downstream targets of p53, such as p21/Waf1 (Mantel 
at al., 1999) and GAAD45 (Hollander and Fomace, 2002), overexpression of 
centrosome associated proteins such as aurora2/STK15/BTAK (Zhou of al., 
1998) and pericentrin (Pihan et at., 2001) and mutations In DNA repair genes 
such as BACRI (Xu at a/., 1999) and BACR2 (Tuft of al., 1999). It Is currently 
not known which of these mechanisms are responsible for the centrosome 
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defects seen in the various cancers or if alternative mechanisms could be 
involved in mediating these effects. 
7.4 THE DEVELOPMENT OF AN IN VITRO MODEL OF CIN IN 
IMMORTALISED HUMAN NORMAL ORAL KERATINOCYTES 
The presence of CIN in cancer has been demonstrated unequivocally (Knuutila 
et al., 1999). Whilst mutations in mitotic checkpoint genes such as BUBI and 
MAD2 have been reported in a limited number of cancers, little is known about 
the mechanisms underlying CIN and how they facilitate cancer progression. The 
development of an in vitro model of CIN, therefore, would greatly facilitate the 
understanding of the cellular and molecular mechanisms underlying human 
carcinogenesis and would likely have implications for cancer therapy and 
prevention in the future. 
Historically, the study of chemical carcinogenesis has relied heavily on the use 
of rodent (Li et al., 1997; Duesberg at al., 2000; Fabarius at al., 2002) or 
malignant (Bardelli at al., 2001) cells. These cells are more susceptible to 
chemical manipulations, as demonstrated by the induction of aneuploldy In a 
100% of Chinese hamster cells after treatment with aromatic polycyclic 
hydrocarbons (Li et al., 1997), but normal human cells have generally been 
shown to be resistant to neoplastic transformation (Rhim, 1991). The present 
study examined the potential of inducing CIN in human immortalised normal 
oral keratinocytes. PhIP, a bulky adduct forming agent belonging to the family of 
heterocyclic aromatic amines (HCA; Schut et al., 1999) was chosen because it 
has been shown previously to induce CIN In malignant cells (Bardelli of al., 
2001). In the present study, human normal oral keratinocytes immortalised with 
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hTERT, the catalytic subunit of telomerase, were used because they have an 
infinite life span in contrast to normal cells that senesce in culture (Dickson et 
al., 2000). Further, the results of this study show that these cells have acquired 
only a small number of genetic alterations, most likely associated with 
immortalisation. In the present study, the development of PhIP-resistance in 
human immortalised normal oral keratinocytes resulted in consistent 
chromosomal abnormalities, as determined by CGH. Compared to the parental 
OKF6/TERT-1 cells, all PhIP-resistant clones exhibited gains of chromosome 8, 
9p21/22-qter and 20 at lower passage (4-5) and an additional gain of 
chromosome 7 in three clones at higher passage (22-25). 
The results of the present study contrast with those of Bardelli et at (2001) who 
showed that the development of PhIP resistance in colorectal cancer cells 
induced a dynamic CIN, which translated to loss or gain of one chromosome for 
every five cell division. These differences might be attributed to the techniques 
employed to evaluate CIN. Bardeli et at (2001) used FISH to examine 
alterations in genome content, whilst CGH was used In the present study. FISH 
is more sensitive compared to CGH, as it is able to detect copy number 
changes of single chromosomes, whilst CGH detects gross changes In the 
genome. Therefore, if CIN was induced in only a small population of cells in the 
present study, it is possible that this might be too low to be detected by CGH. A 
preliminary FISH analysis using a centromeric probe to chromosome 11 
revealed three times more monosomy of chromosome 11 in the PhIP-resistant 
cells compared to the parental cells (data not shown). Whether this reflects the 
presence of a population of cells with ongoing CIN is currently not known. 
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A recent two-step model of carcinogenesis proposed by Rasnick and Duesberg 
(1999) suggests that the initiation step of carcinogenesis involves the 
production of non-cancerous aneuploid cells, which is below the threshold for 
cancer and a latter promotion step allows the threshold of aneuploidy for cancer 
to be reached. It is, therefore, not unreasonable to speculate that the PhIP- 
resistant clones have only reached the initiation stage and it is possible that 
additional inactivation of vital genes, such as p53, might be required to breach 
the threshold for the induction of a dynamic CIN. For example, extensive 
aneuploidy was successfully induced using benzo[a]pyrene in SV40 
immortalised nontumorigenic human lung fibroblast MRC-5 SV2 cells, which 
had inactivated p53 as a result of sequestration by SV40 (Zhu et al., 2002). By 
contrast, the OKF6/TERT-1 cells used in this study have wild type p53 (Dickson 
et a/., 2000) and it would be of great interest to determine if abrogation of p53 in 
the PhIP-resistant clones could induce CIN in these cells or whether p53 
inactivation might be required from the outset. 
It remains a possibility that PhIP cannot induce CIN in normal cells and that the 
consistent chromosome gains observed in the PhIP-resistant clones are specific 
to the development of carcinogen resistance. This Is not unprecedented 
because CGH analysis of PhIP-induced mammary carcinomas in rats showed 
consistent losses in regions of chromosome 2,3,11,18 and X and these 
lesions were suggested to be potentially orthologous to regions of human 
chromosome 5q, 11p, 3p, 18q and X respectively, which harbour deletions in 
certain human breast cancers (Christian et a/., 2002). 
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Having determined that the induction of PhIP resistance resulted in only 
consistent chromosomal changes, the response of the PhIP-resistant clones to 
irradiation induced DNA damage was analysed to determine if the development 
of PhIP-resistance was associated with an altered response to other forms of 
DNA damage. The cellular response to irradiation was assessed in terms of cell 
viability, the induction of apoptosis, the activation of the p53 pathway and cell 
cycle arrest. Both parental and PhIP-resistant clones demonstrated similar 
growth inhibitory and apoptotic responses, had an intact p53 pathway and were 
capable of cell cycle arrest following irradiation. The similarities between the 
parental cells and PhIP resistant clones in their response to irradiation Induced 
DNA damage indicate that the DNA damage response of these clones was not 
altered and, therefore, could not be associated with the induction of PhIP- 
resistance. Recently, Rubio et a!. (2004) showed that telomerase activation 
confers resistance to genotoxic stresses such as irradiation and bleomycin. 
Since the OKF6/TERT-1 parental cells were immortalised through reactivation 
of telomerase, it is not certain if its protective mechanism could mask the 
presence of a damaged DNA response in the PhIP-resistant clones, thus 
conferring resistance to irradiation induced DNA damage. It is also possible that 
this protective mechanism may well have functioned from the beginning to 
prevent the induction of a dynamic CIN in the PhIP treated OKF6/TERT-1 cells. 
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7.5 CONCLUDING REMARKS 
The results of the present study showed that H357 and H400 have an intact 
mitotic checkpoint, whilst the checkpoint could be attenuated in H103, H157, 
H314, H376 and H413 cells. H357 and H376 cells also exhibited a defective 
post-mitotic checkpoint. Although H357 and H376 exhibited centrosome profiles 
that were similar to normal cells, centrosome abnormalities were detected in all 
the remaining cell lines. Furthermore, the study showed that centrosomes in 
H357 and H413 might be defective in monitoring the number of microtubules 
nucleated and cells with high centrosome abnormalities might have an inherent 
defect in maintaining normal centrosome numbers. These results suggest that 
defects of the mitotic and post-mitotic checkpoints and centrosomes could 
singly or co-operatively perpetuate chromosome missegregation. It seems 
likely, therefore, that more than one route exist for the induction of aneuploidy 
and CIN in oral cancer. 
The examination of centrosome abnormalities in the context of DNA ploidy in 
the dysplasias showed that centrosome abnormalities occurred irrespective of 
aneuploidy and increased during the transition from dysplasias to carcinomas. 
This suggests that centrosome abnormalities appear early and precede CIN in 
oral cancer and additional alterations might be required before these 
abnormalities can play an active role in driving oral tumour progression. In this 
study, centrosome abnormalities correlated with a loss of tumour cell 
differentiation in the SCCs suggesting that they could contribute towards tumour 
aggressiveness during the later stages of the disease. 
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Consistent with these observations, an increasing number of studies show that 
a defective post-mitotic or G1/S cell cycle checkpoint could lead to 
tetraploidization of the genome and the consequential inheritance of increased 
centrosome numbers (Sorel et a/., 2002), which could synergise to destabilise 
the genome through chromosome missegregation. Telomere dysfunction could 
further synergise with these mechanisms in perpetuating CIN, as it has been 
shown to occur in conjunction with centrosome abnormalities and aneuploidy 
(Gisselsson et a/., 2002). 
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7.6 FUTURE WORK 
During the course of this study, two areas of research have emerged that are 
likely to have important implications in our understanding of the mechanisms 
underlying CIN in oral cancer. 
The results of Chapter Three have indicated that an attenuated rather than an 
abrogated mitotic checkpoint could be one of the mechanisms underlying CIN in 
oral cancer. Haplo-insufficiency of mitotic checkpoint genes has recently been 
reported to cause attenuation of the mitotic checkpoint (Michel et al., 2001). The 
status of the mitotic checkpoint genes in oral cancer is largely unknown and the 
analysis of the expression of these genes in the OSCC-derived cell lines and 
oral carcinomas would extend the observations of the present study and 
indicate whether haplo-insufficiency of the mitotic checkpoint genes is common 
in oral cancer. 
The results of the present study have indicated that the development of CIN in 
oral cancer is likely to involve multiple mechanisms or pathways. Telomere 
dysfunction is emerging as a potential mechanism leading to CIN as it occurs in 
conjunction with aneuploidy and centrosome abnormalities in head and neck 
tumours (Gisselsson et al., 2002). The consequence of telomeric attrition on the 
stability of the genome and chromosome structure can be first examined in vitro 
using the system created by Rubio et al. (2002), which uses retroviral 
transduction of cells with a combination of Cre-recombinase flanked hTERT, 
catalytic subunit of telomerase, and TIN2, a negative regulator of telomere 
length, to create a population of cells with varying telomere length. The effect of 
short telomeres on the genome can then be investigated using CGH or 
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conventional karyotyping. Furthermore, this model could also be used to study 
telomeres in the context of the mitotic checkpoint or the centrosomes by using 
RNAi to knockdown genes that will lead to defects in these mechanisms, in cells 
with shortened centrosomes. Normal human oral fibroblasts or oral 
keratinocytes would be ideal for such studies, as genetic alterations caused by 
telomere dysfunction could be easily detected against the normal diploid 
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agtgtacacg tcggttgcct aacaaccggc agcggactcc tttggctatg gcctccaact 
ttaagaaggc aaacatggca tcaagttctc agcgaaaaag aatgagccct 
aagcctgagc ttactgaaga gcaaaagcag gagatccggg aagcttttga tcttttcgat 
gcggatggaa ctggcaccat agatgttaaa gaactgaagg tggcaatgag 
ggccctgggc tttgaaccca agaaagaaga aattaagaaa atgataagtg 
aaattgataa ggaagggaca ggaaaaatga actttggtga ctttttaact gtgatgaccc 
agaaaatgtc tgagaaagat actaaagaag aaatcctgaa agctttcaag ctctttgatg 
atgatgaaac tgggaagatt tcgttcaaaa atctgaaacg cgtggccaag 
gagttgggtg agaacctgac tgatgaggag ctgcaggaaa tgattgatga 
agctgatcga gatggagatg gagaggtcag tgagcaagag ttcctgcgca 
tcatgaaaaa gaccagcctc tattaagatc agtgtcttct ttttctactg caagcacatg 
taactagatt tagtgcctgc catggtgtga aatctggctt ttgagaacac aaacttttcc 
cccacggacc tccctttatc actttaatag tgaccttgag cctattttag ccgtttggaa gtgttctttg 
atattacagt tctttgtaaa atgacctgcg aattacccta attctcaaaa gcaaaacaag 
agcacacaag cgtgaagaaa aggatcttaa agctttgagc acctgccatt ttgccttgca 
tcgtttccct cgtcatgcat ttccacatat ccacaaacac agaacgactt tagacaagca 
catgttacac ctgtgttgcc acaagcagtc attcttgacg gctccagttt ttatttgaca cttgagttta 
gttttctctt ttataaaccc agtgaactcc tgcactggca tttggatgtg tgttaatgct atttgttttg 
tcttaaaagt aaaacctttc tcagtttgaa aaaaaaa 
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